<SEC-DOCUMENT>0001144204-19-007289.txt : 20190213
<SEC-HEADER>0001144204-19-007289.hdr.sgml : 20190213
<ACCEPTANCE-DATETIME>20190213170109
ACCESSION NUMBER:		0001144204-19-007289
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20190213
DATE AS OF CHANGE:		20190213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Precipio, Inc.
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-229478
		FILM NUMBER:		19598413

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		203 787 7888

	MAIL ADDRESS:	
		STREET 1:		4 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSGENOMIC INC
		DATE OF NAME CHANGE:	20000119
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>tv513295_424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="margin: 0"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><B></B></P>

<P STYLE="margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed pursuant to Rule 424(b)(3)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Under the Securities Act of 1933, as amended</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration 333-229478</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Up to 15,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Common Stock</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 35pt">This prospectus relates to the offer
and sale of up to 15,000,000 shares of common stock, par value $0.01 per share of Precipio Inc., a Delaware corporation, or the
Company, by Lincoln Park Capital Fund, LLC, or Lincoln Park or the Selling Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 35pt">The shares of common stock being
offered by the Selling Stockholder have been or may be issued pursuant to the purchase agreement dated September 7, 2018, or the
Purchase Agreement, that we entered into with Lincoln Park. See &ldquo;The Lincoln Park Transaction&rdquo; for a description of
the Purchase Agreement and &ldquo;Selling Stockholder&rdquo; for additional information regarding Lincoln Park. The prices at which
Lincoln Park may sell the shares of common stock will be determined by the prevailing market price for the shares of common stock
or in negotiated transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 35pt">We are not selling any securities
under this prospectus and will not receive any of the proceeds from the sale of the shares of common stock by the Selling Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 35pt">The Selling Stockholder may sell
the shares of common stock described in this prospectus in a number of different ways and at varying prices. See &ldquo;Plan of
Distribution&rdquo; for more information about how the Selling Stockholder may sell the shares of common stock being registered
pursuant to this prospectus. The Selling Stockholder is an &ldquo;underwriter&rdquo; within the meaning of Section&nbsp;2(a)(11)
of the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 35pt">We will pay the expenses incurred
in registering the shares of common stock, including legal and accounting fees. See &ldquo;Plan of Distribution&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 35pt">Our common stock is listed on the
NASDAQ Capital Market under the symbol &ldquo;PRPO.&rdquo; On February 11, 2019, the last reported sale price of our common stock
on the NASDAQ Capital Market was $0.16 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Investing in our common stock involves
a high degree of risk. See &ldquo; <U>Risk Factors</U> &rdquo; in this prospectus to read about the factors you should consider
before buying shares of our common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>We may amend or supplement this prospectus
from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or
supplements carefully before you make your investment decision.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 35pt"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The date of
this prospectus is February 13, 2019</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B></B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#s_01"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#s_01"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#s_02"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Offering</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#s_02"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#s_03"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#s_03"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#s_04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#s_04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#s_05"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#s_05">20</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#s_06"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Stockholder</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#s_06"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#s_07"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price Range of Common Stock</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#s_07"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#s_08"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#s_08"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#s_09"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#s_09"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#s_10"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend Policy</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#s_10"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#s_11"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Capital Stock</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#s_11"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#s_12"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan for Distribution</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#s_12"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#s_13"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#s_13"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#s_14"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#s_14"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#s_15"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#s_15"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#s_16"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market and Industry Data and Forecasts</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#s_16"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#s_17"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation of Certain Information by Reference</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#s_17"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">You should rely only on the information contained
in this prospectus or in any free writing prospectus we file with the Securities and Exchange Commission. We have not authorized
anyone to provide you with information different from that contained in this prospectus or any free writing prospectus. We take
no responsibility for, and can provide no assurance, as to the reliability of any other information that others may give you. We
are offering to sell and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted.
The information contained in this prospectus is accurate only as of the date on the front cover of this prospectus, or other earlier
date stated in this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business,
financial condition, results of operations and prospects may have changed since such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">For investors outside of the United States:
we have not done anything that would permit this offering outside the United States or to permit the possession or distribution
of this prospectus outside the United States. Persons outside the United States who come into possession of this prospectus must
inform themselves about and observe any restrictions relating to, the offering of the shares of common stock and the distribution
of this prospectus outside of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><A NAME="s_01"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt"><I>This summary does not contain all of the information
you should consider before buying shares of our common stock. You should read the entire prospectus carefully, especially the &ldquo;Risk
Factors&rdquo; and our Quarterly Report on form 10-Q for the third quarter ended September 30, 2018, filed with the SEC on November
19, 2018 and our financial statements and the related notes our Annual Report on Form&nbsp;10-K&nbsp;for the fiscal year ended
December&nbsp;31, 2017, filed with the SEC on April&nbsp;13, 2018, before deciding to invest in shares of our common stock.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-indent: 0.5in">We are a cancer diagnostics company providing
diagnostic products and services to the oncology market. We have built and continue to develop a platform designed to eradicate
the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering
quality diagnostic information to physicians and their patients worldwide. We operate a cancer diagnostic laboratory located in
New Haven, Connecticut and have partnered with the Yale School of Medicine to capture the expertise, experience and technologies
developed within academia so that we can provide a better standard of cancer diagnostics and aim to solve the growing problem of
cancer misdiagnosis. We also operate a research and development facility in Omaha, Nebraska which will focus on further development
of ICE-COLD-PCR, or ICP, the patented technology described further below, which was exclusively licensed by us from Dana-Farber
Cancer Institute, Inc., or Dana-Farber, at Harvard University. The research and development center focuses on the development of
this technology, which we believe will enable us to commercialize other technologies developed by our current and future academic
partners. Our platform connects patients, physicians and diagnostic experts residing within academic institutions. Launched in
2017, the platform facilitates the following relationships:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Patients: patients may search for physicians in their area and consult directly with academic experts that are on the platform.
Patients may also have access to new academic discoveries as they become commercially available.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Physicians: physicians can connect with academic experts to seek consultations on behalf of their patients and may also provide
consultations for patients in their area seeking medical expertise in that physician&rsquo;s relevant specialty. Physicians will
also have access to new diagnostic solutions to help improve diagnostic accuracy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Academic Experts: academic experts on the platform can make themselves available for patients or physicians seeking access
to their expertise.&nbsp;&nbsp;Additionally, these experts have a platform available to commercialize their research discoveries.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We intend to continue updating our platform
to allow for patient-to-patient communications and allow individuals to share stories and provide support for one another, to allow
physicians to consult with their peers to discuss and share challenges and solutions, and to allow academic experts to interact
with others in academia on the platform to discuss their research and cross-collaborate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">ICP was developed at Harvard and is licensed
exclusively by us from Dana-Farber. The technology enables the detection of genetic mutations in liquid biopsies, such as blood
samples. The field of liquid biopsies is a rapidly growing market, aimed at solving the challenge of obtaining genetic information
on disease progression and changes from sources other than a tumor biopsy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Gene sequencing is performed on tissue biopsies
taken surgically from the tumor site in order to identify potential therapies that will be more effective in treating the patient.
There are several limitations to this process. First, surgical procedures have several limitations, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Cost: surgical procedures are usually performed in a costly hospital environment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Surgical access: various tumor sites are not always accessible (e.g. brain tumors), in which cases no biopsy is available for
diagnosis.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Risk: patient health may not permit undergoing an invasive surgery; therefore, a biopsy cannot be obtained at all.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Time: the process of scheduling and coordinating a surgical procedure often takes time, delaying the start of patient treatment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Second, there are several tumor-related limitations
that provide a challenge to obtaining such genetic information from a tumor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Tumors are heterogeneous by nature: a tissue sample from one area of the tumor may not properly represent the tumor&rsquo;s
entire genetic composition; thus, the diagnostic results from a tumor may be incomplete and non-representative.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Metastases: in order to accurately test a patient with metastatic disease, ideally an individual biopsy sample should be taken
from each site (if those sites are even known). These biopsies are very difficult to obtain; therefore, physicians often rely on
biopsies taken only from the primary tumor site.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The advent of technologies enabling liquid biopsies as an alternative
to tumor biopsy and analysis is based on the fact that tumors (both primary and metastatic) shed cells and fragments of DNA into
the blood stream. These blood samples are called &ldquo;liquid biopsies&rdquo; that contain circulating tumor DNA, or ctDNA, which
hold the same genetic information found in the tumor(s). That tumor DNA is the target of genetic analysis. However, since the quantity
of tumor DNA is very small in proportion to the &ldquo;normal&rdquo; (or &ldquo;healthy&rdquo;) DNA within the blood stream, there
is a need to identify and separate the tumor DNA from the normal DNA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">ICP is an enrichment technology that enables
the laboratory to focus its analysis on the tumor DNA by enriching, and thereby &ldquo;multiplying&rdquo; the presence of, tumor
DNA, while maintaining the normal DNA at its same level. Once the enrichment process has been completed, the laboratory genetic
testing equipment is able to identify genetic abnormalities presented in the ctDNA, and an analysis can be conducted at a higher
level of sensitivity, to enable the detection of such genetic abnormalities. The technology is encapsulated into a chemical that
is provided in the form of a kit and sold to other laboratories who wish to conduct these tests in-house. The chemical within the
kit is added to the specimen preparation process, enriching the sample for the tumor DNA so that the analysis will detect those
genetic abnormalities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt"><B>Risks Associated with Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-indent: 0.5in">Our ability to implement our business
strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks are described
more fully in the section entitled &ldquo;Risk Factors&rdquo; immediately following this prospectus summary. These risks include,
among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a history of recurring losses and an accumulated deficit, which, among other factors, raise doubt about our ability to continue
as a going concern, which in turn may hinder our ability to obtain future financing;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2018, we had a working capital deficit of $8.8 million and we are not current with our liabilities to our vendors and lenders;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will require additional capital in order to continue our operations, and may have difficulty raising additional capital;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have a history of recurring losses; we incurred a net loss of $20.7 million for the year ended December 31, 2017 and we can provide no assurance as to our future operating results;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our stock price has experienced price fluctuations and may continue to do so, thereby adversely affecting our business;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our common stock could be further diluted as the result of the issuance of additional shares of common stock including through the Purchase Agreement with Lincoln Park, convertible securities, warrants or options.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to satisfy Nasdaq listing requirements and our common stock may be delisted, which would adversely impact the price of our securities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On April 20, 2018, the Company entered into a
securities purchase agreement (the &ldquo;Debt Financing Agreement&rdquo;) with certain investors, pursuant to which the Company
issued up to approximately $3.3 million in 8% Senior Secured Convertible Promissory Notes with 100% common stock warrant coverage
in multiple closings which took place on April 20, 2018, July 11, 2018, August 20, 2018 and September 20, 2018. The closing of
the entire transaction under the Debt Financing Agreement provided the Company with $3,000,000 of gross proceeds in consideration
for the issuance of notes with an aggregate principal of $3,296,703. Each note is payable by the Company on the earlier of (i)
the one year anniversary after the original issuance date or (ii) upon the closing of a qualified offering, namely the Company
raising gross proceeds of at least $7,000,000. The obligations under the Notes are secured, subject to certain exceptions and other
permitted payments by a perfected security interest on the assets of the Company. As part of this transaction, the Company issued
to the investors warrants to purchase up to 6,593,407 shares of common stock with an exercise price of $0.50 per share, due to
an amended exercise price from $0.75 to $0.50 per share on September 17, 2018. Half of these warrants have a one-year term and
half have a five-year term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On November 29, 2018, the Company and the investors
amended the above referenced purchase agreement, which we refer to as the Amendment Agreement, to provide for the issuance of up
to $1,318,681 of additional notes together with applicable warrants, in one or more tranche, on substantially the same terms and
conditions as the previously issued notes and warrants. The conversion price of the notes was amended so that it shall be equal
to the greater of $0.25 or $0.05 above the closing bid price of our common stock on the date prior to the original issue date.
In the event the notes are not paid in full prior to 180 days after the original issue date, the conversion price shall be equal
to 80% of the lowest VWAP in the 10 trading days prior to the date of the notice of conversion, but in no event below the floor
price of $0.15. In connection with the amendment, the Company received $1,100,000 of gross proceeds in consideration for the issuance
of notes with an aggregate principal value of $1,208,791 and the Company issued to the investors five year warrants to purchase
up to 4,501,712 shares of common stock with an exercise price of $0.36 per share. The additional Notes and warrants were subscribed
for by the investors that previously participated in the Debt Financing Agreement as well as new investors, including a member
of our Board of Directors. In connection with the Amendment Agreement, the Company entered into a letter agreement with the director
pursuant to which the parties agreed to reprice certain warrants previously issued to the director, so that the exercise price
of those warrants were repriced to $0.50 per share of common stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">On March 12, 2018, we
entered into a settlement agreement (the &ldquo;Crede Agreement&rdquo;) with Crede Capital Group LLC (&ldquo;Crede&rdquo;) pursuant
to which we agreed to pay to Crede a total sum of $1.925 million (the &ldquo;Settlement Amount&rdquo;) over a period of 16 months
payable in a combination of cash and stock in accordance with terms contained in the Crede Agreement. On January 15, 2019, we entered
into an amendment and restatement agreement with Crede (the &ldquo;Crede Amendment&rdquo;), in order to enable the Company to provide
Crede with an alternative means of payment of the Settlement Amount, which was $1.45 million on the date of the Crede Amendment,
by issuing to Crede a convertible note in the amount of $1,450,000 (the &ldquo;Crede Note&rdquo;). The Crede Note was issued on
January 15, 2019, as amended and restated on January 28, 2019, and is payable on the earlier of (i) the two year anniversary after
the original issuance date or (ii) upon the closing of a qualified offering, namely the Company raising gross proceeds of at least
$4,000,000. The Company, at its option, may redeem some or the entire then outstanding principal amount of the Crede Note for cash.
The conversion price of the Crede Note shall equal 90% of the closing bid price of our common stock on the date prior to the conversion
date. Under applicable rules of The NASDAQ Capital Market, in no event may we issue to Crede upon conversion of the Crede Note
more than 19.99% of the shares of our common stock outstanding immediately prior to the execution of the Crede Amendment which
limitation unless we obtain stockholder approval&nbsp;to issue the excess shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">On January 2, 2019,
we entered into a settlement agreement with a third party service provider (the &ldquo;Service Provider&rdquo;) pursuant to which
we agreed to pay the Service Provider an aggregate amount of Five Hundred and Fifty Thousand Dollars ($550,000) (the &ldquo;Settlement
Amount&rdquo;) pursuant to an agreed upon payment schedule in consideration for the cancellation of an outstanding debt owed by
us to the Service Provider in the aggregate amount of $1,470,000 (the &ldquo;Owed Amount&rdquo;). Upon payment in full of the Settlement
Amount, the Service Provider has agreed to waive the difference between the Settlement Amount and the Owed Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">On January 29, 2019,
we entered into a settlement agreement with Leviston Resources LLC (the &ldquo;Leviston Agreement&rdquo;), at which time we issued
to Leviston Resources LLC a convertible note in the amount of $700,000 (the &ldquo;Leviston Note&rdquo;). The Leviston Note is
payable (i) in fourteen equal monthly installments commencing on the earlier to occur of (x) the last day of the month upon which
a registration statement to be filed by the Company covering the resale of the shares of common stock underlying the Note is declared
effective by the Securities and Exchange Commission and (y) the six month anniversary of the date of issuance, (ii) upon the closing
of a qualified offering, namely the Company raising gross proceeds of at least $4,000,000 or (iii) such earlier date as the Leviston
Note is required or permitted to be repaid as provided by its terms. The Company, at its option, may redeem some or the entire
then outstanding principal amount of the Leviston Note for cash. The conversion price in effect on any Conversion Date shall equal
the VWAP of the Common Stock on the date of Conversion Date. Under applicable rules of The NASDAQ Capital Market, in no event may
we issue to Leviston upon conversion of the Leviston Note more than 19.99% of the shares of our common stock outstanding immediately
prior to the execution of the Leviston Agreement which limitation unless we obtain stockholder approval&nbsp;to issue the excess
shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-indent: 0.5in">We were incorporated under the laws of
the State of Delaware in March 1997. Our principal executive office is located at 4 Science Park, New Haven, Connecticut, 06511,
and our telephone number is (203) 787-7888. Our website address is www.precipiodx.com. We do not incorporate the information on
or accessible through our website into this prospectus, and you should not consider any information on, or that can be accessed
through, our website as part of this prospectus. Our current and future annual reports on Form 10-K, quarterly reports on Form
10-Q, current reports on Form 8-K and other filings with the SEC are available, free of charge, through our website as soon as
reasonably practicable after we electronically file such materials with, or furnish them to, the SEC. Our SEC filings can be accessed
through the investors section of our website. The information contained on, or accessible through, our website is not intended
to be part of this prospectus or any report we file with, or furnish to, the SEC and incorporated by reference herein. Our common
stock trades on the NASDAQ Capital Market, or NASDAQ, under the symbol &ldquo;PRPO.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: center"><B><A NAME="s_02"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 39%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock to be offered by the Selling Stockholder hereunder</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 58%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,000,000 shares we may sell to Lincoln Park under the Purchase Agreement from time to time after the date of this prospectus;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock outstanding prior to this offering</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,368,593 shares as of January 29, 2019</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock to be outstanding after giving effect to the issuance of 15,000,000 shares under the Purchase Agreement registered hereunder</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63,368,593 shares</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This prospectus relates to shares of our common stock that may be offered and sold from time to time by Lincoln Park. We will receive no proceeds from the sale of shares of common stock by Lincoln Park in this offering.&nbsp;&nbsp;We may receive up to $10,000,000 aggregate gross proceeds under the Purchase Agreement from any sales we make to Lincoln Park pursuant to the Purchase Agreement. We have previously received $1,615,396 in aggregate gross proceeds from prior sales of 6,400,000 shares under the Purchase Agreement. We have $8,384,604 of gross proceeds remaining from any sales to Lincoln Park under the Purchase Agreement and any proceeds that we receive from such sales will be used for working capital and general corporate purposes. See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk factors</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">This investment involves a high degree of risk. See &ldquo;Risk
        Factors&rdquo; for a discussion of factors you should consider carefully before making an investment decision.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Symbol on The NASDAQ Capital Market</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;PRPO&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Purchase Agreement with Lincoln Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On September 7, 2018, we entered into a purchase
agreement with Lincoln Park, which we refer to in this prospectus as the Purchase Agreement, pursuant to which Lincoln Park has
agreed to purchase from us up to an aggregate of $10,000,000 of our common stock (subject to certain limitations) from time to
time over the term of the Purchase Agreement. Additionally, on September 7, 2018, we entered into a registration rights agreement
with Lincoln Park, which we refer to in this prospectus as the Registration Rights Agreement, pursuant to which we are required
to file with the SEC a registration statement that includes this prospectus to register for resale under the Securities Act of
1933, as amended, or the Securities Act, the shares of common stock that have been or may be issued to Lincoln Park under the Purchase
Agreement. Pursuant to the terms of the Purchase Agreement, we have already issued 600,000 shares of our common stock to Lincoln
Park as consideration for its commitment to purchase shares of our common stock under the Purchase Agreement, which we refer to
in this prospectus as the Commitment Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We do not have the right to commence any sales
of our common stock to Lincoln Park under the Purchase Agreement until certain conditions set forth in the Purchase Agreement,
all of which are outside of Lincoln Park&rsquo;s control, have been satisfied, including that the SEC has declared effective the
registration statement that includes this prospectus. Thereafter, we may, from time to time and at our sole discretion, on any
single business day on which the closing price of our common stock is not less than $0.10 per share (subject to adjustment for
any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction as provided
in the Purchase Agreement), direct Lincoln Park to purchase shares of our common stock in amounts up to 450,000 shares, which amounts
may be increased to up to 550,000 shares depending on the market price of our common stock at the time of sale and subject to a
maximum commitment by Lincoln Park of $1,000,000 per single purchase, which we refer to in this prospectus as &ldquo;regular purchases&rdquo;,
plus other &ldquo;accelerated amounts&rdquo; and/or &ldquo;additional accelerated amounts&rdquo; under certain circumstances. We
will control the timing and amount of any sales of our common stock to Lincoln Park. The purchase price of the shares that may
be sold to Lincoln Park in regular purchases under the Purchase Agreement will be based on the market price of our common stock
preceding the time of sale as computed under the Purchase Agreement. The purchase price per share will be equitably adjusted for
any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the business
days used to compute such price. We may at any time in our sole discretion terminate the Purchase Agreement without fee, penalty
or cost upon one business day notice. &nbsp;There are no restrictions on future financings, rights of first refusal, participation
rights, penalties or liquidated damages in the Purchase Agreement or Registration Rights Agreement, other than a prohibition on
our entering into certain types of transactions that are defined in the Purchase Agreement as &ldquo;Variable Rate Transactions&rdquo;.
Lincoln Park may not assign or transfer its rights and obligations under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of January 29, 2019, there were 48,368,593
shares of our common stock outstanding, of which 46,288,972 shares were held by non-affiliates. As of the date of this prospectus,
we have already received approximately $1,615,396 from the sale of 6,400,000 shares of common stock to Lincoln Park which were
registered on a Registration Statement on Form S-1A (File No.: 333-227364). Although the Purchase Agreement provides that we may
sell up to $10,000,000 of our common stock to Lincoln Park, only 15,000,000 additional shares of our common stock are being offered
under this prospectus, which may be issued to Lincoln Park, if and when we sell shares to Lincoln Park under the Purchase Agreement.
Depending on the market prices of our common stock at the time we elect to issue and sell shares to Lincoln Park under the Purchase
Agreement, we may need to register additional shares of our common stock in order to receive aggregate gross proceeds equal to
the $10,000,000 total commitment available to us under the Purchase Agreement. We have previously received $1,615,396 in aggregate
gross proceeds from prior sales of 6,400,000 shares under the Purchase Agreement. We have $8,384,604 of gross proceeds remaining
from any sales to Lincoln Park under the Purchase Agreement. If all of the 15,000,000 shares offered by Lincoln Park under this
prospectus were issued and outstanding as of January 29, 2019, such shares would represent approximately 23.7% of the total number
of shares of our common stock outstanding and approximately 24.5% of the total number of outstanding shares held by non-affiliates,
in each case as of the date hereof. If we elect to issue and sell more than the 15,000,000 shares offered under this prospectus
to Lincoln Park, which we have the right, but not the obligation, to do, we must first register for resale under the Securities
Act any such additional shares, which could cause additional substantial dilution to our stockholders. The number of shares ultimately
offered for resale by Lincoln Park is dependent upon the number of shares we sell to Lincoln Park under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Under applicable rules of The NASDAQ Capital
Market, in no event may we issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of our common
stock outstanding immediately prior to the execution of the Purchase Agreement which limitation we refer to as the Exchange Cap,
unless (i) we obtain stockholder approval&nbsp;to issue shares of common stock in excess of the Exchange Cap or (ii) the average
price of all applicable sales of our common stock to Lincoln Park under the Purchase Agreement equals or exceeds $0.4728 (which
represents the closing consolidated bid price of our common stock on September 7, 2018, plus an incremental amount to account for
our issuance of the Commitment Shares to Lincoln Park), such that issuances and sales of our common stock to Lincoln Park under
the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable NASDAQ rules. On December 20, 2018, we
received the requisite approval of our shareholders to issue shares of common stock in excess of the Exchange Cap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Purchase Agreement also prohibits us from
directing Lincoln Park to purchase any shares of common stock if those shares, when aggregated with all other shares of our common
stock then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial
ownership, at any single point in time, of more than 4.99% of the then total outstanding shares of our common stock, as calculated
pursuant to Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and Rule&nbsp;13d-3 thereunder,
which limitation we refer to as the Beneficial Ownership Cap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Issuances of our common stock in this offering
will not affect the rights or privileges of our existing stockholders, except that the economic and voting interests of each of
our existing stockholders will be diluted as a result of any such issuance. Although the number of shares of common stock that
our existing stockholders own will not decrease, the shares owned by our existing stockholders will represent a smaller percentage
of our total outstanding shares after any such issuance to Lincoln Park.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><A NAME="s_03"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Investing in our common stock involves a high degree of risk.
You should carefully consider the risks and uncertainties described below together with all of the other information contained
in this prospectus, including our financial statements and the related notes in our Quarterly report on form 10Q for the fiscal
quarter ended September 30, 2018, filed with the SEC on November 19, 2018 and our Annual Report on Form&nbsp;10-K&nbsp;for the
fiscal year ended December&nbsp;31, 2017, filed with the SEC on April&nbsp;13, 2018, before deciding to invest in our common stock.
If any of the following risks actually occur, our business, prospects, operating results and financial condition could suffer materially,
the trading price of our common stock could decline and you could lose all or part of your investment. Additional risks and uncertainties
not presently known to us or that we currently believe to be immaterial may also adversely affect our business.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Risks Related to Our Business and Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>There is substantial doubt about our ability to continue as
a going concern.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our Independent Registered Public Accounting
Firm has issued an opinion on our Consolidated Financial Statements included in our Annual Report on Form&nbsp;10-K&nbsp;for the
fiscal year ended December&nbsp;31, 2017, filed with the SEC on April&nbsp;13, 2018, that states that the Consolidated Financial
Statements were prepared assuming we will continue as a going concern. Our consolidated financial statements have been prepared
using generally accepted accounting principles, or GAAP, applicable for a going concern, which assume that we will realize our
assets and discharge our liabilities in the ordinary course of business. We have incurred substantial operating losses and have
used cash in our operating activities for the past few years. For the year ended December 31, 2017, we had a net loss of $20.7
million, negative working capital of $8.3 million and net cash used in operating activities of $6.7 million. For the nine months
ended September 30, 2018, we had a net loss of $9.1 million, negative working capital of $8.8 million and net cash used in operating
activities of $4.8 million We are not current in making payments to all lenders and vendors. Our consolidated financial statements
do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable
to continue as a going concern. We also cannot be certain that additional financing, if needed, will be available on acceptable
terms, or at all, and our failure to raise capital when needed could limit our ability to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">To date, we have experienced negative cash flow
from development of our diagnostic technology, as well as from the costs associated with establishing a laboratory and building
a sales force to market our products and services.&nbsp;We expect to incur substantial net losses for the foreseeable future to
further develop and commercialize our diagnostic technology.&nbsp;We also expect that our selling, general and administrative expenses
will continue to increase due to the additional costs associated with market development activities and expanding our staff to
sell and support our products. Our ability to achieve or, if achieved, sustain profitability is based on numerous factors, many
of which are beyond our control, including the market acceptance of our products, competitive product development and our market
penetration and margins. We may never be able to generate sufficient revenue to achieve or, if achieved, sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Because of the numerous risks and uncertainties
associated with further development and commercialization of our diagnostic technology and any future tests, we are unable to predict
the extent of any future losses or when we will become profitable, if ever.&nbsp;We may never become profitable and you may never
receive a return on an investment in our securities.&nbsp;An investor in our securities must carefully consider the substantial
challenges, risks and uncertainties inherent in the development and commercialization of tests in the medical diagnostic industry.&nbsp;We
may never successfully commercialize our diagnostic technology or any future tests, and our business may fail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We will require significant additional financing to sustain
our operations and without it we will not be able to continue operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">At September 30, 2018, we had a working capital
deficit of $8.8 million. We had an operating cash flow deficit of $4.8 million for the nine months ended September 30, 2018 and
$6.7 million for the year ended December 31, 2017. We do not currently have sufficient financial resources to fund our operations
or those of our subsidiaries. Therefore, we need additional funds to continue these operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may direct Lincoln Park to purchase up to
$10,000,000 worth of shares of our common stock under our agreement over a 24-month period generally in amounts up to 450,000 shares
of our common stock, which may be increased to up to 550,000 shares of our common stock depending on the market price of our common
stock at the time of sale and subject to a maximum commitment by Lincoln Park of $1,000,000 per regular purchase, on any business
day on which the closing price of our common stock is not less than $0.10 per share (subject to adjustment for any reorganization,
recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction as provided in the Purchase
Agreement). Assuming a purchase price of $0.19 per share (the closing sale price of the common stock on January 29, 2019) and the
purchase by Lincoln Park of 15,000,000 purchase shares, total gross proceeds to us would only be approximately $2.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The extent we rely on Lincoln Park as a source
of funding will depend on a number of factors including, the prevailing market price of our common stock and the extent to which
we are able to secure working capital from other sources. If obtaining sufficient funding from Lincoln Park were to prove unavailable
or prohibitively dilutive, we will need to secure another source of funding in order to satisfy our working capital needs. Even
if we sell all $10,000,000 under the Purchase Agreement to Lincoln Park, we may still need additional capital to fully implement
our business, operating and development plans. Should the financing we require to sustain our working capital needs be unavailable
or prohibitively expensive when we require it, the consequences could be a material adverse effect on our business, operating results,
financial condition and prospects. As of the date of this prospectus, we have already received approximately $1,615,396 from the
sale of 6,400,000 shares of common stock to Lincoln Park.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We will need to raise substantial additional capital to commercialize
our diagnostic technology, and our failure to obtain funding when needed may force us to delay, reduce or eliminate our product
development programs or collaboration efforts or force us to restrict or cease operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of September 30, 2018, we had cash of $0.2
million and our working capital was approximately negative $8.8 million. Due to our recurring losses from operations and the expectation
that we will continue to incur losses in the future, we will be required to raise additional capital to complete the development
and commercialization of our current product candidates and to pay off our obligations.&nbsp;To date, to fund our operations and
develop and commercialize our products, we have relied primarily on equity and debt financings. When we seek additional capital,
we may seek to sell additional equity and/or debt securities or to obtain a credit facility, which we may not be able to do on
favorable terms, or at all.&nbsp;Our ability to obtain additional financing will be subject to a number of factors, including market
conditions, our operating performance and investor sentiment.&nbsp;If we are unable to raise additional capital when required or
on acceptable terms, we may have to significantly delay, scale back or discontinue the development and/or commercialization of
one or more of our product candidates, restrict or cease our operations or obtain funds by entering into agreements on unattractive
terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp; <B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We have incurred losses since our inception and expect to
incur losses for the foreseeable future. We cannot be certain that we will achieve or sustain profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have incurred losses since our inception
and expect to incur losses in the future. As of September 30, 2018, we had a net loss of $9.1 million, negative working capital
of $8.8 million and net cash used in operating activities of $4.8 million. For the nine months ended September 30, 2018, we have
experienced negative cash flow from development of our diagnostic technology, as well as from the costs associated with establishing
a laboratory and building a sales force to market our products and services. We expect to incur substantial net losses for the
foreseeable future to further develop and commercialize our diagnostic technology. We also expect that our selling, general and
administrative expenses will continue to increase due to the additional costs associated with market development activities and
expanding our staff to sell and support our products. Our ability to achieve or, if achieved, sustain profitability is based on
numerous factors, many of which are beyond our control, including the market acceptance of our products, competitive product development
and our market penetration and margins. We may never be able to generate sufficient revenue to achieve or, if achieved, sustain
profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Because of the numerous risks and uncertainties
associated with further development and commercialization of our diagnostic technology and any future tests, we are unable to predict
the extent of any future losses or when we will become profitable, if ever. We may never become profitable and you may never receive
a return on an investment in our securities. An investor in our securities must carefully consider the substantial challenges,
risks and uncertainties inherent in the development and commercialization of tests in the medical diagnostic industry. We may never
successfully commercialize our diagnostic technology or any future tests, and our business may fail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We have been, and may continue to be, subject to costly litigation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have been, and may continue to be, subject
to legal proceedings. Due to the nature of our business and our lack of sufficient capital resources to pay our obligations on
a timely basis, we may be subject to a variety of regulatory investigations, claims, lawsuits and other proceedings in the ordinary
course of our business. The results of these legal proceedings cannot be predicted with certainty due to the uncertainty inherent
in litigation, including the effects of discovery of new evidence or advancement of new legal theories, the difficulty of predicting
decisions of judges and juries and the possibility that decisions may be reversed on appeal. Such litigation has been, and in the
future, could be, costly, time-consuming and distracting to management, result in a diversion of resources and could materially
adversely affect our business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, we may settle some litigation through
the issuance of equity securities which may result in significant dilution to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>The commercial success of our product candidates will depend
upon the degree of market acceptance of these products among physicians, patients, health care payors and the medical community
and on our ability to successfully market our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our products may never gain significant acceptance
in the marketplace and, therefore, may never generate substantial revenue or profits for us. Our ability to achieve commercial
market acceptance for our existing and future products will depend on several factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to convince the medical community of the clinical utility of our products and their potential advantages over existing
diagnostics technology;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the willingness of physicians and patients to utilize our products; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the agreement by commercial third-party payors and government payors to reimburse our products, the scope and amount of which will affect patients&rsquo; willingness or ability to pay for our products and will likely heavily influence physicians&rsquo; decisions to recommend our products.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, physicians may rely on guidelines
issued by industry groups, such as the National Comprehensive Cancer Network, medical societies, such as the College of American
Pathologists, or CAP, or other key oncology-related organizations before utilizing any diagnostic test. Although we have a study
underway to demonstrate the clinical utility of our existing products, none of our products are, and may never be, listed in any
such guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We believe that publications of scientific and
medical results in peer-reviewed journals and presentations at leading conferences are critical to the broad adoption of our products.
Publication in leading medical journals is subject to a peer-review process, and peer reviewers may not consider the results of
studies involving our products sufficiently novel or worthy of publication. The failure to be listed in physician guidelines or
to be published in peer-reviewed journals could limit the adoption of our products. Failure to achieve widespread market acceptance
of our products would materially harm our business, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>If we cannot compete successfully with our competitors, including
new entrants in the market, we may be unable to increase or sustain our revenue or achieve and sustain profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The medical diagnostic industry is intensely
competitive and characterized by rapid technological progress.&nbsp;We face significant competition from competitors ranging in
size from diversified global companies with significant research and development resources to small, specialized firms whose narrower
product lines may allow them to be more effective in deploying related PCR technology in the genetic diagnostic industry. Our closest
competitors fall largely into two groups, consisting of companies that specialize in oncology and offer directly competing services
to our diagnostic services, offering their services to oncologists and pathology departments within hospitals, as well as large
commercial companies that offer a wide variety of laboratory tests that range from simple chemistry tests to complex genetic testing.&nbsp;The
technologies associated with the molecular diagnostics industry are evolving rapidly and there is intense competition within such
industry.&nbsp;Certain molecular diagnostics companies have established technologies that may be competitive to our product candidates
and any future tests that we develop.&nbsp;Some of these tests may use different approaches or means to obtain diagnostic results,
which could be more effective or less expensive than our tests for similar indications.&nbsp;Moreover, these and other future competitors
have or may have considerably greater resources than we do in terms of technology, sales, marketing, commercialization and capital
resources.&nbsp;These competitors may have substantial advantages over us in terms of research and development expertise, experience
in clinical studies, experience in regulatory issues, brand name exposure and expertise in sales and marketing as well as in operating
central laboratory services.&nbsp;Many of these organizations have financial, marketing and human resources greater than ours;
therefore, there can be no assurance that we can successfully compete with present or potential competitors or that such competition
will not have a materially adverse effect on our business, financial position or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In July 2017, we commenced a study to demonstrate
the impact of academic pathology expertise on diagnostic accuracy. There is no assurance that this study, or other studies or trials
we may conduct, will demonstrate favorable results. If the results of this study, or other studies or trials we may conduct, demonstrate
unfavorable or inconclusive results, customers may choose our competitors&rsquo; products over our products and our commercial
opportunities may be reduced or eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We believe that many of our competitors spend
significantly more on research and development-related activities than we do.&nbsp;Our competitors may discover new diagnostic
tools or develop existing technologies to compete with our diagnostic technology.&nbsp;Our commercial opportunities will be reduced
or eliminated if these competing products are more effective, are more convenient or are less expensive than our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We may not be able to develop new products or enhance the
capabilities of our systems to keep pace with rapidly changing technology and customer requirements, which could have a material
adverse effect on our business and operating results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our success depends on our ability to develop
new products and applications for our diagnostic technology in existing and new markets, while improving the performance and cost-effectiveness
of our systems. New technologies, techniques or products could emerge that might offer better combinations of price and performance
than our current or future products and systems. Existing or future markets for our products, as well as potential markets for
our diagnostic product candidates, are characterized by rapid technological change and innovation. It is critical to our success
that we anticipate changes in technology and customer requirements and successfully introduce new, enhanced and competitive technologies
to meet our customers&rsquo; and prospective customers&rsquo; needs on a timely and cost-effective basis. At the same time, however,
we must carefully manage the introduction of new products. If customers believe that such products will offer enhanced features
or be sold for a more attractive price, they may delay purchases until such products are available. We may also have excess or
obsolete inventory of older products as we transition to new products and our experience in managing product transitions is very
limited. If we do not successfully innovate and introduce new technology into our product lines or effectively manage the transitions
to new product offerings, our revenues and results of operations will be adversely impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Competitors may respond more quickly and effectively
than we do to new or changing opportunities, technologies, standards or customer requirements. We anticipate that we will face
increased competition in the future as existing companies and competitors develop new or improved products and as new companies
enter the market with new technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We currently depend on the services of pathologists at a single
academic partner and the loss of the services of these pathologists would adversely impact our ability to develop, commercialize
and deliver our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We currently depend on the services of pathologists
at a single academic partner to review and render their diagnostic interpretation of our test results and to prepare the final
diagnostic results that we integrate into our final report for our customers. Although we are in the process of adding new academic
partners, it would be difficult to replace the services provided by the pathologists at our current partner if their services became
unavailable to us for any reason prior to adding other academic partners. If this academic partner does not successfully carry
out its contractual duties or obligations and meet expected deadlines; if this partner needs to be replaced, or if the quality
or accuracy of the services provided by the pathologists at this partner were compromised for any reason, we would likely not be
able to provide our services in a manner expected by our customers, and our financial results and the commercial prospects for
our products could be harmed. The loss of the services of these pathologists would severely harm our ability to develop, commercialize
and deliver our products, and our business, financial condition and operating results would be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We may experience temporary disruptions and delays in processing
biological samples at our facilities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may experience delays in processing biological
samples caused by software and other errors. Any delay in processing samples could have an adverse effect on our business, financial
condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We depend upon a limited number of key personnel, and if we
are not able to retain them or recruit additional qualified personnel, the commercialization of our product candidates and any
future tests that we develop could be delayed or negatively impacted.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our success is largely dependent upon the continued
contributions of our officers and employees.&nbsp;Our success also depends in part on our ability to attract and retain highly
qualified scientific, commercial and administrative personnel.&nbsp;In order to pursue our test development and commercialization
strategies, we will need to attract and hire additional personnel with specialized experience in a number of disciplines, including
assay development, laboratory and clinical operations, sales and marketing, billing and reimbursement.&nbsp;There is intense competition
for personnel in the fields in which we operate.&nbsp;If we are unable to attract new employees and retain existing employees,
the development and commercialization of our product candidates and any future tests could be delayed or negatively impacted. If
any of them becomes unable or unwilling to continue in their respective positions, and we are unable to find suitable replacements,
our business and financial results could be materially negatively affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We will need to increase the size of our organization, and
we may experience difficulties in managing growth.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are a small company with 44 full-time employees
as of September 30, 2018.&nbsp;Future growth will impose significant added responsibilities on members of management, including
the need to identify, attract, retain, motivate and integrate highly skilled personnel.&nbsp;We may increase the number of employees
in the future depending on the progress of our development of diagnostic technology.&nbsp;Our future financial performance and
our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any
future growth effectively.&nbsp;To that end, we must be able to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">integrate additional management, administrative, manufacturing and regulatory personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain sufficient administrative, accounting and management information systems and controls; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire and train additional qualified personnel.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;We may not be able to accomplish these
tasks, and our failure to accomplish any of them could harm our financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We currently have limited experience in marketing products.&nbsp;If
we are unable to establish marketing and sales capabilities and retain the proper talent to execute on our sales and marketing
strategy, we may not be able to generate product revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have developed limited experience in marketing
our products and services.&nbsp;We intend to continue to develop our in-house marketing organization and sales force, which will
require significant capital expenditures, management resources and time. We will have to compete with other diagnostic companies
to recruit, hire, train and retain marketing and sales personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we are unable to further grow our internal
sales, marketing and distribution capabilities, we may pursue collaborative arrangements regarding the sales and marketing of our
product candidates or future products, however, we may not be able to establish or maintain such collaborative arrangements, or
if we are able to do so, they may not have effective sales forces.&nbsp;Any revenue we receive will depend upon the efforts of
such third parties, which may not be successful.&nbsp;We may have little or no control over the marketing and sales efforts of
such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves.&nbsp;We
also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Cybersecurity risks could compromise our information and expose
us to liability, which may harm our ability to operate effectively and may cause our business and reputation to suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Cybersecurity refers to the combination of technologies,
processes and procedures established to protect information technology systems and data from unauthorized access, attack, or damage.
We rely on our information systems to provide security for processing, transmission and storage of confidential information about
our patients, customers and personnel, such as names, addresses and other individually identifiable information protected by the
Health Insurance Portability and Accountability Act, (&ldquo;HIPAA&rdquo;), other privacy laws. Cyber-attacks are increasingly
more common, including in&nbsp;the health care industry. The regulatory environment surrounding information security and privacy
is increasingly demanding, with the frequent imposition of new and changing requirements.&nbsp;Compliance with changes in privacy
and information security laws and with rapidly evolving industry standards&nbsp;may result in our incurring significant expense
due to increased investment in technology and the development of new operational processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have not experienced any known attacks on
our information technology systems that compromised any confidential information. We maintain our information technology systems
with safeguard protection against cyber-attacks including passive intrusion protection, firewalls and virus detection software.
However, these safeguards do not ensure that a significant cyber-attack could not occur. Although we have taken steps to protect
the security of our information systems and the data maintained in those systems, it is possible that our safety and security measures
will not prevent the systems&rsquo; improper functioning or damage or the improper access or disclosure of personally identifiable
information such as in the event of cyber-attacks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Security breaches, including physical or electronic
break-ins, computer viruses, attacks by hackers and similar breaches can create system disruptions or shutdowns or the unauthorized
disclosure of confidential information. If personal information or protected health information is improperly accessed, tampered
with or disclosed as a result of a security breach, we may incur significant costs to notify and mitigate potential harm to the
affected individuals, and we may be subject to sanctions and civil or criminal penalties if we are found to be in violation of
the privacy or security rules under HIPAA or other similar federal or state laws protecting confidential personal information.
In addition, a security breach of our information systems could damage our reputation, subject us to liability claims or regulatory
penalties for compromised personal information and could have a material adverse effect on our business, financial condition and
results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Our ability to use net operating loss carryforwards to offset
future taxable income for U.S. federal tax purposes is subject to limitation and risk that could further limit our ability to utilize
our net operating losses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Under U.S. federal income tax law, a corporation&rsquo;s
ability to utilize its net operating losses, or NOLs, to offset future taxable income may be significantly limited if it experiences
an &ldquo;ownership change&rdquo; as defined in Section&nbsp;382 of the Internal Revenue Code, as amended. In general, an ownership
change will occur if there is a cumulative change in a corporation&rsquo;s ownership by &ldquo;5-percent shareholders&rdquo; that
exceeds 50&nbsp;percentage points over a rolling three-year period. A corporation that experiences an ownership change will generally
be subject to an annual limitation on the use of its pre-ownership change NOLs equal to the value of the corporation immediately
before the ownership change, multiplied by the long-term tax-exempt rate (subject to certain adjustments). The annual limitation
for a taxable year generally is increased by the amount of any &ldquo;recognized built-in gains&rdquo; for such year and the amount
of any unused annual limitation in a prior year. On December 22, 2017, a law commonly known as the Tax Cuts and Jobs Act, or the
TCJ Act, was enacted in the United States. Certain provisions of the TCJ Act impact the ability to utilize NOLs generated in 2018
and forward; any limitation to our annual use of NOLs could require us to pay a greater amount of U.S. federal (and in some cases,
state) income taxes, which could reduce our after-tax income from operations for future taxable years and adversely impact our
financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Reimbursement and Regulatory Risks Relating
to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Governmental payers and health care plans have taken steps
to control costs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Medicare, Medicaid and private insurers have
increased their efforts to control the costs of health care services, including clinical testing services. They may reduce fee
schedules or limit/exclude coverage for certain types of tests that we perform. Medicaid reimbursement varies by state and is subject
to administrative and billing requirements and budget pressures. We expect efforts to reduce reimbursements, impose more stringent
cost controls and reduce utilization of testing services will continue. These efforts, including changes in laws or regulations,
may have a material adverse impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Changes in payer mix could have a material adverse impact
on our net sales and profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Testing services are billed to physicians, patients,
government payers such as Medicare, and insurance companies. Tests may be billed to different payers depending on a particular
patient&rsquo;s medical insurance coverage. Government payers have increased their efforts to control the cost, utilization and
delivery of health care services as well as reimbursement for laboratory testing services. Further reductions of reimbursement
for Medicare and Medicaid services or changes in policy regarding coverage of tests or other requirements for payment, such as
prior authorization or a physician or qualified practitioner&rsquo;s signature on test requisitions, may be implemented from time
to time. Reimbursement for the laboratory services component of our business is also subject to statutory and regulatory reduction.
Reductions in the reimbursement rates and changes in payment policies of other third party payers may occur as well. Such changes
in the past have resulted in reduced payments as well as added costs and have decreased test utilization for the clinical laboratory
industry by adding more complex new regulatory and administrative requirements. As a result, increases in the percentage of services
billed to government payers could have an adverse impact on our net sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Our laboratories require ongoing CLIA certification.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Clinical Laboratory Improvement Amendments
of 1988, or CLIA, extended federal oversight to virtually all clinical laboratories by requiring that they be certified by the
federal government or by a federally-approved accreditation agency. The CLIA requires that all clinical laboratories meet quality
assurance, quality control and personnel standards. Laboratories must also undergo proficiency testing and are subject to inspections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The sanctions for failure to comply with the
CLIA requirements include suspension, revocation or limitation of a laboratory&rsquo;s CLIA certificate, which is necessary to
conduct business, cancellation or suspension of the laboratory&rsquo;s approval to receive Medicare and/or Medicaid reimbursement,
as well as significant fines and/or criminal penalties. The loss or suspension of a CLIA certification, imposition of a fine or
other penalties, or future changes in the CLIA law or regulations (or interpretation of the law or regulations) could have a material
adverse effect on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We believe that we are in compliance with all
applicable laboratory requirements, but no assurances can be given that our laboratories will pass all future certification inspections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Failure to comply with HIPAA could be costly.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">HIPAA and associated regulations protect the
privacy and security of certain patient health information and establish standards for electronic health care transactions in the
United States. These privacy regulations establish federal standards regarding the uses and disclosures of protected health information.
Our laboratories are subject to HIPAA and its associated regulations. If we fail to comply with these laws and regulations we could
suffer civil and criminal penalties, fines, exclusion from participation in governmental health care programs and the loss of various
licenses, certificates and authorizations necessary to operate our patient testing business. We could also incur liabilities from
third party claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Our failure to comply with any applicable government laws
and regulations or otherwise respond to claims relating to improper handling, storage or disposal of hazardous chemicals that we
use may adversely affect our results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our research and development and commercial
activities involve the controlled use of hazardous materials and chemicals. We are subject to federal, state, local and international
laws and regulations governing the use, storage, handling and disposal of hazardous materials and waste products. If we fail to
comply with applicable laws or regulations, we could be required to pay penalties or be held liable for any damages that result
and this liability could exceed our financial resources. We cannot be certain that accidental contamination or injury will not
occur. Any such accident could damage our research and manufacturing facilities and operations, resulting in delays and increased
costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We may become subject to the Anti-Kickback Statute, Stark
Law, False Claims Act, Civil Monetary Penalties Law and may be subject to analogous provisions of applicable state laws and could
face substantial penalties if we fail to comply with such laws.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">There are several federal laws addressing fraud
and abuse that apply to businesses that receive reimbursement from a federal health care program. There are also a number of similar
state laws covering fraud and abuse with respect to, for example, private payors, self-pay and insurance. Currently, we receive
a substantial percentage of our revenue from private payors and from Medicare. Accordingly, our business is subject to federal
fraud and abuse laws, such as the Anti-Kickback Statute, the Stark Law, the False Claims Act, the Civil Monetary Penalties Law
and other similar laws. Moreover, we are already subject to similar state laws. We believe we have operated, and intend to continue
to operate, our business in compliance with these laws. However, these laws are subject to modification and changes in interpretation,
and are enforced by authorities vested with broad discretion. Federal and state enforcement entities have significantly increased
their scrutiny of healthcare companies and providers which has led to investigations, prosecutions, convictions and large settlements.
We continually monitor developments in this area. If these laws are interpreted in a manner contrary to our interpretation or are
reinterpreted or amended, or if new legislation is enacted with respect to healthcare fraud and abuse, illegal remuneration, or
similar issues, we may be required to restructure our affected operations to maintain compliance with applicable law. There can
be no assurances that any such restructuring will be possible or, if possible, would not have a material adverse effect on our
results of operations, financial position, or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Anti-Kickback Statute</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A federal law commonly referred to as the &ldquo;Anti-Kickback
Statute&rdquo; prohibits the knowing and willful offer, payment, solicitation or receipt of remuneration, directly or indirectly,
in return for the referral of patients or arranging for the referral of patients, or in return for the recommendation, arrangement,
purchase, lease or order of items or services that are covered, in whole or in part, by a federal healthcare program such as Medicare
or Medicaid. The term &ldquo;remuneration&rdquo; has been broadly interpreted to include anything of value such as gifts, discounts,
rebates, waiver of payments or providing anything at less than its fair market value. The Patient Protection and Affordable Care
Act, as amended by the Health Care and Education Reconciliation Act, or the PPACA, amended the intent requirement of the Anti-Kickback
Statute such that a person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific
intent to violate the statute. Further, the PPACA now provides that claims submitted in violation of the Anti-Kickback Statute
constitute false or fraudulent claims for purposes of the federal False Claims Act, or FCA, including the failure to timely return
an overpayment. Many states have adopted similar prohibitions against kickbacks and other practices that are intended to influence
the purchase, lease or ordering of healthcare items and services reimbursed by a governmental health program or state Medicaid
program. Some of these state prohibitions apply to remuneration for referrals of healthcare items or services reimbursed by any
third-party payor, including commercial payors and self-pay patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Stark Law</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Section&nbsp;1877 of the Social Security Act,
or the Stark Law, prohibits a physician from referring a patient to an entity for certain &ldquo;designated health services&rdquo;
reimbursable by Medicare if the physician (or close family members) has a financial relationship with that entity, including an
ownership or investment interest, a loan or debt relationship or a compensation relationship, unless an exception to the Stark
Law is fully satisfied. The designated health services covered by the law include, among others, laboratory and imaging services.
Some states have self-referral laws similar to the Stark Law for Medicaid claims and commercial claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Violation of the Stark Law may result in prohibition
of payment for services rendered, a refund of any Medicare payments for services that resulted from an unlawful referral, $15,000
civil monetary penalties for specified infractions, criminal penalties, and potential exclusion from participation in government
healthcare programs, and potential false claims liability. The repayment provisions in the Stark Law are not dependent on the parties
having an improper intent; rather, the Stark Law is a strict liability statute and any violation is subject to repayment of all
amounts arising out of tainted referrals. If physician self-referral laws are interpreted differently or if other legislative restrictions
are issued, we could incur significant sanctions and loss of revenues, or we could have to change our arrangements and operations
in a way that could have a material adverse effect on our business, prospects, damage to our reputation, results of operations
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>False Claims Act</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The FCA prohibits providers from, among other
things, (1)&nbsp;knowingly presenting or causing to be presented, claims for payments from the Medicare, Medicaid or other federal
healthcare programs that are false or fraudulent; (2)&nbsp;knowingly making, using or causing to be made or used, a false record
or statement to get a false or fraudulent claim paid or approved by the federal government; or (3)&nbsp;knowingly making, using
or causing to be made or used, a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal
government. The &ldquo;qui tam&rdquo; or &ldquo;whistleblower&rdquo; provisions of the FCA allow private individuals to bring actions
under the FCA on behalf of the government. These private parties are entitled to share in any amounts recovered by the government,
and, as a result, the number of &ldquo;whistleblower&rdquo; lawsuits that have been filed against providers has increased significantly
in recent years. Defendants found to be liable under the FCA may be required to pay three times the actual damages sustained by
the government, plus civil penalties ranging between $5,500 and $11,000 for each separate false claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">There are many potential bases for liability
under the FCA. The government has used the FCA to prosecute Medicare and other government healthcare program fraud such as coding
errors, billing for services not provided, and providing care that is not medically necessary or that is substandard in quality.
The PPACA also provides that claims submitted in connection with patient referrals that result from violations of the Anti-Kickback
Statute constitute false claims for the purpose of the FCA, and some courts have held that a violation of the Stark law can result
in FCA liability, as well. In addition, a number of states have adopted their own false claims and whistleblower provisions whereby
a private party may file a civil lawsuit in state court. We are required to provide information to our employees and certain contractors
about state and federal false claims laws and whistleblower provisions and protections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Civil Monetary Penalties Law</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Civil Monetary Penalties Law prohibits,
among other things, the offering or giving of remuneration to a Medicare or Medicaid beneficiary that the person or entity knows
or should know is likely to influence the beneficiary&rsquo;s selection of a particular provider or supplier of items or services
reimbursable by a federal or state healthcare program. This broad provision applies to many kinds of inducements or benefits provided
to patients, including complimentary items, services or transportation that are of more than a nominal value. This law could affect
how we have to structure our operations and activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Intellectual Property Risks Related to Our
Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We cannot be certain that measures taken to protect our intellectual
property will be effective.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We rely upon trade secrets, copyright and trademark
laws, non-disclosure agreements and other contractual confidentiality provisions to protect our confidential and proprietary information
that we are not seeking patent protection for various reasons. Such measures, however, may not provide adequate protection for
our trade secrets or other proprietary information. If such measures do not protect our rights, third parties could use our technology
and our ability to compete in the market would be reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We depend on certain technologies that are licensed to us.
We do not control these technologies and any loss of our rights to them could prevent us from selling some of our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have entered into license agreements with
third parties for certain licensed technologies that are, or may become, relevant to the products we market, or plan to market,
including our license agreement with Dana-Farber Cancer Institute, Inc., pursuant to which we license our ICE-COLD-PCR technology.
In addition, we may in the future elect to license third party intellectual property to further our business objectives and/or
as needed for freedom to operate for our products. We do not and will not own the patents, patent applications or other intellectual
property rights that are the subject of these licenses. Our rights to use these technologies and employ the inventions claimed
in the licensed patents, patent applications and other intellectual property rights are or will be subject to the continuation
of and compliance with the terms of those licenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We might not be able to obtain licenses to technology
or other intellectual property rights that we require. Even if such licenses are obtainable, they may not be available at a reasonable
cost or multiple licenses may be needed for the same product (e.g., stacked royalties). We could therefore incur substantial costs
related to royalty payments for licenses obtained from third parties, which could negatively affect our gross margins. Further,
we could encounter delays in product introductions, or interruptions in product sales, as we develop alternative methods or products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In some cases, we do not or may not control
the prosecution, maintenance, or filing of the patents or patent applications to which we hold licenses, or the enforcement of
these patents against third parties. As a result, we cannot be certain that drafting or prosecution of the licensed patents and
patent applications by the licensors have been or will be conducted in compliance with applicable laws and regulations or will
result in valid and enforceable patents and other intellectual property rights.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Third parties may assert ownership or
commercial rights to inventions we develop.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Third parties may in the future make claims
challenging the inventorship or ownership of our intellectual property. For example, third parties that have been introduced to
or have benefited from our inventions may attempt to replicate or reverse engineer our products and circumvent ownership of our
inventions. In addition, we may face claims that our agreements with employees, contractors, or consultants obligating them to
assign intellectual property to us are ineffective, or in conflict with prior or competing contractual obligations of assignment,
which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our
ability to capture the commercial value of such inventions. Litigation may be necessary to resolve an ownership dispute, and if
we are not successful, we may be precluded from using certain intellectual property, or may lose our exclusive rights in that intellectual
property. Either outcome could have an adverse impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Third parties may assert that our employees or consultants
have wrongfully used or disclosed confidential information or misappropriated trade secrets.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Although we try to ensure that our employees
and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims
that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual
property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may
be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we
may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation
could result in substantial costs and be a distraction to management and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>The testing, manufacturing and marketing of medical diagnostic
devices entails an inherent risk of product liability and personal injury claims.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">To date, we have experienced no product liability
or personal injury claims, but any such claims arising in the future could have a material adverse effect on our business, financial
condition and results of operations.&nbsp;Potential product liability or personal injury claims may exceed the amount of our insurance
coverage or may be excluded from coverage under the terms of our policy or limited by other claims under our umbrella insurance
policy.&nbsp;Additionally, our existing insurance may not be renewed by us at a cost and level of coverage comparable to that presently
in effect, if at all.&nbsp;In the event that we are held liable for a claim against which we are not insured or for damages exceeding
the limits of our insurance coverage, such claim could have a material adverse effect on our cash flow and thus potentially a materially
adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>All of our diagnostic technology development and our clinical
services are performed at two laboratories, and in the event either or both of these facilities were to be affected by a termination
of the lease or a man-made or natural disaster, our operations could be severely impaired.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are performing all of our diagnostic services
in our CLIA laboratory located in New Haven, Connecticut and our research and development operations are based in our facility
in Omaha, Nebraska.&nbsp;Despite precautions taken by us, any future natural or man-made disaster at these laboratories, such as
a fire, earthquake or terrorist activity, could cause substantial delays in our operations, damage or destroy our equipment and
testing samples or cause us to incur additional expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, we are leasing the facilities where
our laboratories operate.&nbsp;We are currently in compliance with all and any lease obligations, but should the leases terminate
for any reason, or if at any time either of the laboratories is moved due to conditions outside our control, it could cause substantial
delay in our diagnostics operations, damage or destroy our equipment and biological samples or cause us to incur additional expenses.&nbsp;In
the event of an extended shutdown of either laboratory, we may be unable to perform our services in a timely manner or at all and
therefore would be unable to operate in a commercially competitive manner.&nbsp;This could harm our operating results and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Further, if we have to use a substitute laboratory
while our facilities were shut down, we could only use another facility with established state licensure and accreditation under
CLIA.&nbsp;We may not be able to find another CLIA-certified facility and comply with applicable procedures, or find any such laboratory
that would be willing to perform the tests for us on commercially reasonable terms.&nbsp;Additionally, any new laboratory opened
by us would be subject to certification under CLIA and licensure by various states, which would take a significant amount of time
and result in delays in our ability to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Risks Related to Our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>The price of our common stock may fluctuate significantly,
which could negatively affect us and holders of our common stock.</I></B> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">There has been, and continues to be, a limited
public market for our common stock, and an active trading market for our common stock has not and may never develop or, if developed,
be sustained. The trading price of our common stock may be highly volatile and could be subject to wide fluctuations in response
to various factors, some of which are beyond our control. These factors include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">These factors include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated fluctuations in our financial condition and operating results:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated changes in our growth rate relative to our competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition from existing products or new products that may emerge;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us, our academic institution partners, or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations, or capital commitments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public and the revision of any financial estimates and projections that we provide to the public;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance of new or updated research or reports by securities analysts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions, transitions or departures of key management or scientific personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes or other developments related to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies, or other aspects of our business;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes to reimbursement levels by commercial third-party payors and government payors, including Medicare, and any announcements relating to reimbursement levels;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcement or expectation of additional debt or equity financing efforts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our common stock by us, our insiders, or our other stockholders; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic and market conditions</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">These and other market and industry factors
may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance,
which may limit or prevent investors from readily selling their shares of our common stock and may otherwise negatively affect
the liquidity of our common stock. In addition, the stock market in general has experienced price and volume fluctuations that
have often been unrelated or disproportionate to the operating performance of these companies. In the past, when the market price
of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that
issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit.
Such a lawsuit could also divert the time and attention of our management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>The price of our stock may be vulnerable to manipulation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We believe our common stock has been the subject
of significant short selling by certain market participants. Short sales are transactions in which a market participant sells a
security that it does not own. To complete the transaction, the market participant must borrow the security to make delivery to
the buyer. The market participant is then obligated to replace the security borrowed by purchasing the security at the market price
at the time of required replacement. If the price at the time of replacement is lower than the price at which the security was
originally sold by the market participant, then the market participant will realize a gain on the transaction. Thus, it is in the
market participant&rsquo;s interest for the market price of the underlying security to decline as much as possible during the period
prior to the time of replacement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Because our unrestricted public float has been
small relative to other issuers, previous short selling efforts have impacted, and may in the future continue to impact, the value
of our stock in an extreme and volatile manner to our detriment and the detriment of our shareholders. Efforts by certain market
participants to manipulate the price of our common stock for their personal financial gain may cause our stockholders to lose
a portion of their investment, may make it more difficult for us to raise equity capital when needed without significantly diluting
existing stockholders, and may reduce demand from new investors to purchase shares of our stock.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>If we cannot continue to satisfy NASDAQ listing maintenance
requirements and other rules, our common stock may be delisted, which could negatively impact the price of our securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Although our common stock is listed on the NASDAQ
Capital Market, we may be unable to continue to satisfy the listing maintenance requirements and rules. If we are unable to satisfy
The NASDAQ Stock Market, or NASDAQ, criteria for maintaining our listing, our securities could be subject to delisting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On March 26, 2018, we received a letter from
NASDAQ notifying us that for the past 30 consecutive business days, the closing bid price per share of our common stock was below
the $1.00 minimum bid price requirement for continued listing on the NASDAQ Capital Market, as required by NASDAQ Listing Rule
5550(a)(2), or the Bid Price Rule. As a result, we were notified by NASDAQ that we are not in compliance with the Bid Price Rule.
NASDAQ has provided us with 180 calendar days, or until September 24, 2018, to regain compliance with the Bid Price Rule. On September
25, 2018, we received a letter from NASDAQ notifying us that we are eligible for an additional 180 day extension, or until March
25, 2019, to regain compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">To regain compliance with the Bid Price Rule,
the closing bid price of our common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during
the additional 180 day grace period. If our common stock does not regain compliance with the Bid Price Rule during this grace period,
we will receive written notification from NASDAQ that our securities will be delisted. At that time, we may appeal to a Hearing&rsquo;s
Panel and will have to provide a plan to regain compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are presently evaluating various courses
of action to regain compliance with the Bid Price Rule. However, there can be no assurance that we will be able to regain compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If NASDAQ delists our securities, we could face
significant consequences, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a limited availability for market quotations for our securities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced liquidity with respect to our securities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a determination that our common stock is a &ldquo;penny stock,&rdquo; which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in reduced trading;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">activity in the secondary trading market for our common stock;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited amount of news and analyst coverage; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a decreased ability to issue additional securities or obtain additional financing in the future.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, we would no longer be subject to
NASDAQ rules, including rules requiring us to have a certain number of independent directors and to meet other corporate governance
standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Increased costs associated with corporate governance compliance
may significantly impact our results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As a public company, we incur significant legal,
accounting, and other expenses due to our compliance with regulations and disclosure obligations applicable to us, including compliance
with the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as rules implemented by the SEC, and NASDAQ. The SEC and
other regulators have continued to adopt new rules and regulations and make additional changes to existing regulations that require
our compliance. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted.
There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that have required
the SEC to adopt additional rules and regulations in these areas. Stockholder activism, the current political environment, and
the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure
obligations, which may lead to additional compliance costs and impact, in ways we cannot currently anticipate, the manner in which
we operate our business. Our management and other personnel devote a substantial amount of time to these compliance programs and
monitoring of public company reporting obligations, and as a result of the new corporate governance and executive compensation
related rules, regulations, and guidelines prompted by the Dodd-Frank Act, and further regulations and disclosure obligations expected
in the future, we will likely need to devote additional time and costs to comply with such compliance programs and rules. These
rules and regulations will cause us to incur significant legal and financial compliance costs and will make some activities more
time-consuming and costly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Sarbanes-Oxley Act requires that we maintain
effective disclosure controls and procedures and internal control over financial reporting. We are continuing to develop and refine
our disclosure controls and other procedures that are designed to ensure that information required to be disclosed by us in the
reports that we file with the SEC is recorded, processed, summarized, and reported within the time periods specified in SEC rules
and forms, and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our
principal executive and financial officers. Our current controls and any new controls that we develop may become inadequate, and
weaknesses in our internal control over financial reporting may be discovered in the future. Any failure to develop or maintain
effective controls could adversely affect the results of periodic management evaluations and annual independent registered public
accounting firm attestation reports regarding the effectiveness of our internal control over financial reporting, which we may
be required to include in our periodic reports that we file with the SEC under Section&nbsp;404 of the Sarbanes-Oxley Act, and
could harm our operating results, cause us to fail to meet our reporting obligations, or result in a restatement of our prior period
financial statements. If we are not able to demonstrate compliance with the Sarbanes-Oxley Act, that our internal control over
financial reporting is perceived as inadequate, or that we are unable to produce timely or accurate financial statements, investors
may lose confidence in our operating results, and the price of our common stock could decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are required to comply with certain of the
SEC rules that implement Section&nbsp;404 of the Sarbanes-Oxley Act, which requires management to certify financial and other information
in our quarterly and annual reports and provide an annual management report on the effectiveness of our internal control over financial
reporting. This assessment needs to include the disclosure of any material weaknesses in our internal control over financial reporting
identified by our management or our independent registered public accounting firm. During the evaluation and testing process, if
we identify one or more material weaknesses in our internal control over financial reporting or if we are unable to complete our
evaluation, testing, and any required remediation in a timely fashion, we will be unable to assert that our internal control over
financial reporting is effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">These developments could make it more difficult
for us to retain qualified members of our Board of Directors, or qualified executive officers. We are presently evaluating and
monitoring regulatory developments and cannot estimate the timing or magnitude of additional costs we may incur as a result. To
the extent these costs are significant, our general and administrative expenses are likely to increase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We have not paid dividends on our common stock in the past
and do not expect to pay dividends on our common stock for the foreseeable future.&nbsp; Any return on investment may be limited
to the value of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">No cash dividends have been paid on our common
stock.&nbsp; We expect that any income received from operations will be devoted to our future operations and growth.&nbsp; We do
not expect to pay cash dividends on our common stock in the near future.&nbsp; Payment of dividends would depend upon our profitability
at the time, cash available for those dividends, and other factors as our board of directors may consider relevant.&nbsp; If we
do not pay dividends, our common stock may be less valuable because a return on an investor&rsquo;s investment will only occur
if our stock price appreciates.&nbsp; Investors in our common stock should not rely on an investment in our company if they require
dividend income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>If securities or industry analysts do not publish research
or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading
volume could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The trading market for our common stock relies
in part on the research and reports that equity research analysts publish about us and our business. We do not control these analysts.
The price of our common stock could decline if one or more equity research analysts downgrade our common stock or if they issue
other unfavorable commentary or cease publishing reports about us or our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>The sale or issuance of our common stock to Lincoln Park may
cause significant dilution and the sale of the shares of common stock acquired by Lincoln Park, or the perception that such sales
may occur, could cause the price of our common stock to fall</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On September 7, 2018, we entered into the Purchase
Agreement with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up to $10,000,000 of our common stock. Upon
the execution of the Purchase Agreement, we issued 600,000 Commitment Shares to Lincoln Park as a fee for its commitment to purchase
shares of our common stock under the Purchase Agreement. The remaining shares of our common stock that may be issued under the
Purchase Agreement may be sold by us to Lincoln Park at our discretion from time to time over a 24-month period commencing after
the satisfaction of certain conditions set forth in the Purchase Agreement, including that the SEC has declared effective the registration
statement that includes this prospectus. The purchase price for the shares that we may sell to Lincoln Park under the Purchase
Agreement will fluctuate based on the price of our common stock. Depending on market liquidity at the time, sales of such shares
may cause the trading price of our common stock to fall.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We generally have the right to control the timing
and amount of any future sales of our shares to Lincoln Park. Additional sales of our common stock, if any, to Lincoln Park will
depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to Lincoln Park all, some
or none of the additional shares of our common stock that may be available for us to sell pursuant to the Purchase Agreement. If
and when we do sell shares to Lincoln Park, after Lincoln Park has acquired the shares, Lincoln Park may resell all, some or none
of those shares at any time or from time to time in its discretion. Therefore, sales to Lincoln Park by us could result in substantial
dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our
common stock to Lincoln Park, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related
securities in the future at a time and at a price that we might otherwise wish to effect sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of the date of this prospectus, we have already
received approximately $1,615,396 from the sale of 6,400,000 shares of common stock to Lincoln Park.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>The issuance of our common stock to creditors or litigants
may cause significant dilution to our stockholders and cause the price of our common stock to fall</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may seek to settle outstanding obligations
to vendors, debtholders or litigants in any litigation through the issuance of our common stock or other security to such persons.
Such issuances may cause significant dilution to our stockholders and cause the price of our common stock to fall.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="s_04"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This prospectus, including the sections entitled
&ldquo;Prospectus Summary,&rdquo; &ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations&rdquo; and &ldquo;Business,&rdquo; contains forward-looking statements that are based on our management&rsquo;s
belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected
in these forward-looking statements are reasonable, these statements relate to our strategy, future operations, future financial
position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, and involve known
and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements
to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these
forward-looking statements. Forward-looking statements in this prospectus include, but are not limited to, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
use of the net proceeds from this offering;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress, timing and amount of expenses associated with our development and commercialization activities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our plans and ability to develop and commercialize new products and services, and make improvements to our existing products and services;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability or the amount of time it will take to achieve successful reimbursement of our existing and future products and services from third-party payors, such as commercial insurance companies and health maintenance organizations, and government insurance programs, such as Medicare and Medicaid;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the accuracy of our estimates of the size and characteristics of the markets that may be addressed by our products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success of our study to demonstrate the impact of academic pathology expertise on diagnostic accuracy, and any other studies or trials we may conduct;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our intention to seek, and our ability to establish, strategic collaborations or partnerships for the development or sale of our products and the effectiveness of such collaborations or partnerships;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations as to future financial performance, expense levels and liquidity sources;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in; vertical-align: top"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our anticipated cash needs and our estimates regarding our capital requirements and our needs for additional financing, as well as our ability to obtain such additional financing on reasonable terms;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in; vertical-align: top"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to compete with other companies that are or may be developing or selling products that are competitive with our products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 14pt">&bull;</FONT></TD><TD>our ability to build a sales force to market our products and services, and anticipated increases in our sales and marketing
costs due to an expansion in our sales force and marketing activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 14pt">&bull;</FONT></TD><TD>federal and state regulatory requirements, including potential United States Food and Drug Administration regulation of our
products or future products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 14pt">&bull;</FONT></TD><TD>anticipated trends and challenges in our potential markets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 14pt">&bull;</FONT></TD><TD>our ability to attract and retain key personnel; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 14pt">&bull;</FONT></TD><TD>other factors discussed elsewhere in this prospectus.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In some cases, you can identify forward-looking
statements by terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo;
&ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo;
&ldquo;continue&rdquo; or the negative of these terms or other comparable terminology. These statements are only predictions. You
should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other
factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual
results to differ materially from current expectations include, among other things, those listed under &ldquo;Risk Factors&rdquo;
and elsewhere in this prospectus. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove
to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements.
No forward-looking statement is a guarantee of future performance. You should read this prospectus and the documents that we reference
in this prospectus and have filed with the SEC as exhibits to the registration statement, of which this prospectus is a part, completely
and with the understanding that our actual future results may be materially different from any future results expressed or implied
by these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The forward-looking statements in this prospectus
represent our views as of the date of this prospectus. We anticipate that subsequent events and developments will cause our views
to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current
intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking
statements as representing our views as of any date subsequent to the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><A NAME="s_05"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus relates to shares of our
common stock that may be offered and sold from time to time by Lincoln Park. We will receive no proceeds from the sale of shares
of common stock by Lincoln Park in this offering. We may receive up to $10,000,000 aggregate gross proceeds from any sales we make
to Lincoln Park pursuant to the Purchase Agreement. We estimate that the net proceeds to us from the sale of our common stock to
Lincoln Park pursuant to the Purchase Agreement will be up to $9,865,000 over an approximately 24-month period, assuming that we
sell the full amount of our common stock that we have the right, but not the obligation, to sell to Lincoln Park under that agreement
and other estimated fees and expenses. See &ldquo;Plan of Distribution&rdquo; in this prospectus for more information. As of the
date of this prospectus, we have $8,384,604 of aggregate proceeds remaining having already received approximately $1,615,396 from
the sale of 6,400,000 shares of common stock to Lincoln Park exclusive of the 15,000,000 shares of common stock registered hereunder.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We expect to use any proceeds that we receive
under the Purchase Agreement for working capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><B><A NAME="s_06"></A>SELLING STOCKHOLDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This prospectus relates to the possible resale
by the selling stockholder, Lincoln Park, of shares of common stock that have been or may be issued to Lincoln Park pursuant to
the Purchase Agreement. We are filing the registration statement of which this prospectus forms a part pursuant to the provisions
of the Registration Rights Agreement, which we entered into with Lincoln Park on September 7, 2018 concurrently with our execution
of the Purchase Agreement, in which we agreed to provide certain registration rights with respect to sales by Lincoln Park of the
shares of our common stock that have been or may be issued to Lincoln Park under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Lincoln Park, as the selling stockholder, may,
from time to time, offer and sell pursuant to this prospectus any or all of the shares that we have issued or may sell to Lincoln
Park under the Purchase Agreement. The selling stockholder may sell some, all or none of its shares. We do not know how long the
selling stockholder will hold the shares before selling them, and we currently have no agreements, arrangements or understandings
with the selling stockholder regarding the sale of any of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following table presents information regarding
the selling stockholder and the shares that it may offer and sell from time to time under this prospectus. The table is prepared
based on information supplied to us by the selling stockholder, and reflects its holdings as of January 29, 2019. Neither Lincoln
Park nor any of its affiliates has held a position or office, or had any other material relationship, with us or any of our predecessors
or affiliates. Beneficial ownership is determined in accordance with Section&nbsp;13(d) of the Exchange Act and Rule&nbsp;13d-3
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Selling Stockholder</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares <BR>
Beneficially<BR> Owned Before <BR>
this<BR> Offering</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Percentage of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Outstanding<BR> Shares<BR> Beneficially<BR> Owned Before<BR> this Offering</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Shares to be <BR>
Sold in this<BR> Offering <BR>
Assuming <BR>
The<BR> Company <BR>
issues the<BR> Maximum <BR>
Number of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Shares Under <BR>
the</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Purchase<BR> Agreement</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Percentage of<BR> Outstanding<BR> Shares</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Beneficially</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Owned After&nbsp;this</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Offering</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Lincoln Park Capital Fund, LLC (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,026,183</TD><TD STYLE="width: 1%; text-align: left">(2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2.08</TD><TD NOWRAP STYLE="width: 1%; text-align: left">%(3)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">15,000,000</TD><TD STYLE="width: 1%; text-align: left">(4)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2.08</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh
Scheinfeld and Jonathan Cope, the Managing Members of Lincoln Park Capital, LLC, are deemed to be beneficial owners of all of
the shares of common stock owned by Lincoln Park Capital Fund, LLC. Messrs. Cope and Scheinfeld have shared voting and investment
power over the shares being offered under the prospectus filed with the SEC in connection with the transactions contemplated under
the Purchase Agreement. Lincoln Park Capital, LLC is not a licensed broker dealer or an affiliate of a licensed broker dealer.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
(i) an aggregate of 1,023,116 shares of our common stock issuable upon conversion of convertible promissory notes and (ii) an
aggregate of 3,067 shares of our common stock issuable upon exercise of warrants to purchase our common stock, at certain fixed
prices (that may be subject to adjustment as provided in such warrants), which warrants were acquired by Lincoln Park in connection
with prior public offerings of securities. Lincoln Park may not convert these notes or exercise these warrants if such shares,
when aggregated with all other shares of our common stock then beneficially owned by Lincoln Park and its affiliates, would result
in Lincoln Park and its affiliates having beneficial ownership of more than 4.99% of the then total outstanding shares of our
common stock, as calculated in accordance with the terms of such warrants. In accordance with rule 13d-3(d) under the Exchange
Act, we have excluded from the number of shares beneficially owned prior to the offering all of the shares of common stock that
Lincoln Park may be required to purchase pursuant to the Purchase Agreement because the issuance of such shares is solely at our
discretion and is subject to certain conditions, the satisfaction of all of which are outside of Lincoln Park&rsquo;s control,
including the registration statement of which this prospectus is a part becoming and remaining effective. Furthermore, under the
terms of the Purchase Agreement, issuances and sales of shares of our common stock to Lincoln Park are subject to certain limitations
on the amounts we may sell to Lincoln Park at any time, including the Exchange Cap and the Beneficial Ownership Cap. See the description
under the heading &ldquo;The Lincoln Park Transaction&rdquo; for more information about the Purchase Agreement.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on 48,368,593 outstanding shares of our common stock as of January 29, 2019.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the Purchase Agreement provides that we may sell up to $10,000,000 of our common stock to Lincoln Park, only 15,000,000 shares
of our common stock are being offered under this prospectus, which may be sold by us to Lincoln Park at our discretion from time
to time over a 24-month period commencing after the satisfaction of certain conditions set forth in the Purchase Agreement, including
that the SEC has declared effective the registration statement that includes this prospectus. Depending on the price per share
at which we sell our common stock to Lincoln Park pursuant to the Purchase Agreement, we may need to sell to Lincoln Park under
the Purchase Agreement more shares of our common stock than are offered under this prospectus in order to receive aggregate gross
proceeds equal to the $10,000,000 total commitment available to us under the Purchase Agreement. If we choose to do so, we must
first register for resale under the Securities Act such additional shares. The number of shares ultimately offered for resale
by Lincoln Park is dependent upon the number of shares we sell to Lincoln Park under the Purchase Agreement. As of the date of
this prospectus, we have $8,384,064 of aggregate proceeds remaining having already received approximately $1,615,396 from the
sale of 6,400,000 shares of common stock to Lincoln Park pursuant to a registration statement on form S-1A with registration number
333-227364.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="s_07"></A>PRICE RANGE OF COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Since June 30, 2017, the trading date following
the consummation of the Merger, our common stock has traded on the NASDAQ Capital Market under the symbol &ldquo;PRPO.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Prior to the Merger, our common stock was traded
on the NASDAQ Capital Market under the symbol &ldquo;TBIO.&rdquo; Our common stock was suspended from trading on the NASDAQ Capital
Market on February 17, 2017, and on February 22, 2017, our shares began trading on the OTCQB exchange under the ticker &ldquo;TBIO&rdquo;
and remained on the OTCQB exchange until the date of the Merger. In connection with the merger, our common stock commenced trading
on the NASDAQ Capital Market under the symbol &ldquo;PRPO.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following table sets forth, for the periods
indicated, the closing prices of our common stock as reported on the market exchanges noted above. The over-the-counter market
quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual
transactions. The per share prices reflect a 1-for-30 reverse stock split effected on June 13, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal Year 2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%">First Quarter (through January 29, 2019)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.26</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.16</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal Year 2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">First Quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1.30</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.48</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.55</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.36</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.51</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.33</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal Year 2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">First Quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">33.60</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">7.80</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16.86</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.90</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.80</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.08</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal Year 2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">First Quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">32.41</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">16.20</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">21.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">15.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">17.36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8.37</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11.04</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.75</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On January 29, 2019, the closing price of our
common stock as reported on The NASDAQ Capital Market was $0.19 per share. As of January 29, 2019, there were approximately 76
holders of record and 48,368,593 shares of our common stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><A NAME="s_08"></A>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following table sets forth our cash and
cash equivalents and capitalization as of September 30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
an actual basis</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on a pro forma basis to give effect to:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
receipt of $1,100,000, in the fourth quarter of 2018, pursuant to the Amendment Agreement. There were two closings under the Amendment
Agreement that provided the Company with $1,100,000 of proceeds for the issuance of notes with an aggregate principal of $1,208,791.
As part of these closings, we issued to the investors five-year warrants to purchase up to 4,501,712 shares of our common stock
with an exercise price of $0.36. Estimated debt discount and debt issuance costs related to these notes were approximately $1,100,000;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the issuance of 11,486,093 shares of our common stock, subsequent to September 30, 2018, as a result of the conversion of convertible promissory notes, associated with the Debt Financing Agreement, totaling approximately $1,606,000;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the issuance of approximately $941,000 in convertible promissory notes (the &ldquo;Exchange Notes&rdquo;), subsequent to September 30, 2018, that were issued in exchange for secured debt obligations of the Company totaling $1,058,000. As of September 30, 2018, the Company already had $1,823,000 of Exchange Notes outstanding. Estimated debt discounts related to the new Exchange Notes were approximately $122,000;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the issuance of 6,703,715 shares of our common stock, subsequent to September 30, 2018, as a result of the conversion of Exchange Notes, totaling approximately $2,765,000;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the receipt of approximately $1,615,396 subsequent to September 30, 2018, as a result of the sale of 6,400,000 shares of common stock to Lincoln Park pursuant to a registration statement on form S-1A with registration number 333-227364 filed on September 13, 2018; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the issuance of 22,913 shares of our common stock, subsequent to September 30, 2018, as a result of a restricted stock grant to a third party service provider.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on a pro forma as adjusted basis to give further effect to (i)&nbsp;our sale of&nbsp;15,000,000 shares of common stock in this offering and our receipt of the net proceeds therefrom at an assumed public offering price of $0.19 per share, after deducting estimated offering expenses payable by us.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">The following information
is illustrative only, and our cash and capitalization following the completion of the sale to Lincoln Park of the shares registered
for resale pursuant to this prospectus will change based on the per share price of the common stock sold to Lincoln Park. You should
read this table in conjunction with &quot;Management's Discussion and Analysis of Financial Condition and Results of Operations&quot;
and our condensed consolidated financial statements and related notes in our Quarterly Report on Form&nbsp;10-Q&nbsp;for the quarter
ended September 30, 2018, filed with the SEC on November 19, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of September 30, 2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Actual</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Pro Forma</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Pro Forma<BR> As Adjusted</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center">(in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-indent: -10pt; padding-left: 10pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">219</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,934</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,699</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Current maturities of long-term debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">653</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">360</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">360</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Current maturities of convertible notes, less debt discounts and debt issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">256</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">187</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">187</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Long-term debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,036</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">271</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">271</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Convertible notes, less debt discounts and debt issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,530</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Common stock warrant liability and derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,030</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,550</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,550</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Capital leases (current &amp; long term)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Stockholders' equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Preferred stock, $0.01 par value per share; 15,000,000 shares authorized, actual, pro forma and pro forma as adjusted, 47 shares of Series B Preferred Stock issued and outstanding as of September 30, 2018, actual, pro forma and pro forma as adjusted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Common stock, $0.001 par value per share; 150,000,000 shares authorized, actual, pro forma and pro forma as adjusted;&nbsp;23,755,872 shares issued and outstanding at September 30, 2018, actual; 48,368,593 shares issued and outstanding, pro forma;&nbsp;63,368,593 shares issued and outstanding, pro forma as adjusted;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">483</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">634</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,063</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,314</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,928</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(41,121</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42,765</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42,765</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Total stockholders' equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,180</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,032</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,797</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Total capitalization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,450</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,439</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13,204</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The preceding data is based on 48,368,593 shares
outstanding as of January 29, 2019. This number excludes the following, all of which, if issued by the Company, would be dilutive
to our stockholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,399,076
common shares issuable upon the exercise of stock options outstanding as of January 29, 2019, at a weighted average exercise price
of $1.06 per share;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,763,608 shares of common stock issuable upon exercise of warrants that were outstanding as of January 29, 2019 at a weighted-average exercise price of $1.25 per share;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,665,289 shares of common stock reserved for future issuance under our 2017 Stock Option and Incentive Plan, as well as any automatic increases in the number of common shares reserved for issuance under the 2017 Stock Option and Incentive Plan after the date of this prospectus ;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">313,333 shares of our common stock issuable upon conversion of 47 shares of our Series&nbsp;B Preferred Stock; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,972,219 shares of common stock issuable upon conversion of convertible promissory notes outstanding as of January 29, 2019, which amount may increase significantly if certain notes are not repaid or converted within 180 days of the issuance or if there is a decline in the Company&rsquo;s stock price.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Also, to the extent that we issue any common
stock to vendors, lenders, litigants or potential litigants, the issuance of such securities could result in significant dilution
to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><A NAME="s_09"></A>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If you invest in our common stock, your interest
will be diluted to the extent of the difference between the public offering price per share of our common stock and the pro forma
as adjusted net tangible book value per share of our common stock after this offering. As of September 30, 2018, our historical
net tangible book value was $(13.5) million, or $(0.57) per share of common stock, based on 23,755,872 shares of our common stock
outstanding at September 30, 2018. Our historical net tangible book value per share represents the amount of our total tangible
assets reduced by the amount of our total liabilities, divided by the total number of shares of our common stock outstanding as
of September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our pro forma net tangible book value as of
September 30, 2018 was $(8.6)&nbsp;million, or $(0.18)&nbsp;per share of common stock. Pro forma net tangible book value per share
represents total tangible assets less total liabilities, divided by the number of shares of common stock outstanding, assuming
(i) the receipt of $1,100,000, in the fourth quarter of 2018, for the issuance of notes with an aggregate principal of $1,208,791;
(ii) the issuance of 11,486,093 shares of our common stock, subsequent to September 30, 2018, as a result of the conversion of
convertible promissory notes, associated with the Debt Financing Agreement, totaling approximately $1,606,000; (iii) the issuance
of approximately $941,000 in Exchange Notes, subsequent to September 30, 2018, that were issued in exchange for secured debt obligations
of the Company totaling $1,058,000; (iv) the issuance of 6,703,715 shares of our common stock, subsequent to September 30, 2018,
as a result of the conversion of Exchange Notes, totaling approximately $2,765,000; (v) the receipt of approximately $1,615,396,
subsequent to September 30, 2018, as a result of the sale of 6,400,000 shares of common stock to Lincoln Park; and, (vi) the issuance
of 22,913 shares of our common stock, subsequent to September 30, 2018, as a result of a restricted stock grant to a third party
service provider.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">After giving effect to the sale by us of&nbsp;15,000,000
shares of our common stock in this offering at the assumed public offering price of $0.19 per share, after deducting estimated
offering expenses payable by us, our pro forma as adjusted net tangible book value as of September 30, 2018 would have been $(5.9)&nbsp;million,
or $(0.09)&nbsp;per share. This represents an immediate increase in pro forma net tangible book value of $0.09 per share to our
existing stockholders and an immediate dilution of $0.28 per share to our new investors purchasing shares of common stock in this
offering. The following table illustrates this dilution on a per share basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed public offering price per share</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.19</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical net tangible book value per share as of September 30, 2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.57</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in net tangible book value per share attributable to the pro forma adjustments described above</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.39</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro forma net tangible book value per share as of September 30, 2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.18</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in pro forma net tangible book value per share attributable to this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.09</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro forma as adjusted net tangible book value per share after this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.09</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution per share to new investors in this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.28</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The preceding data is based on 48,368,593 shares
outstanding as of January 29, 2019. This number excludes the following, all of which, if issued by the Company, would be dilutive
to our stockholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,399,076 common shares issuable upon the exercise of stock options outstanding as of January 29, 2019, at a weighted average exercise price of $1.06 per share;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,763,608 shares of common stock issuable upon exercise of warrants that were outstanding as of January 29, 2019 at a weighted-average exercise price of $1.25 per share;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,665,289 shares of common stock reserved for future issuance under our 2017 Stock Option and Incentive Plan, as well as any automatic increases in the number of common shares reserved for issuance under the 2017 Stock Option and Incentive Plan after the date of this prospectus;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">313,333 shares of our common stock issuable upon conversion of 47 shares of our Series&nbsp;B Preferred Stock; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,972,219 shares of common stock issuable upon conversion of convertible promissory notes outstanding as of January 29, 2019, which amount may increase significantly if certain notes are not repaid or converted within 180 days of the issuance or if there is a decline in the Company&rsquo;s stock price.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">To the extent that stock options are exercised
or new stock options are issued under our equity incentive plans, there will be further dilution to investors purchasing common
stock in this offering. In addition, we need to raise additional capital because of market conditions and strategic considerations.
If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could
result in further dilution to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Also, to the extent that we issue any common
stock to vendors, lenders, litigants or potential litigants, the issuance of such securities could result in significant dilution
to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp; <B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><A NAME="s_10"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have never declared or paid dividends on
our capital stock. We do not anticipate paying any dividends on our capital stock in the foreseeable future. We currently intend
to retain all available funds and any future earnings to fund the development and growth of our business. Any future determination
to declare dividends will be subject to the discretion of our board of directors and will depend on various factors, including
applicable laws, our results of operations, financial condition, future prospects and any other factors deemed relevant by our
board of directors. Investors should not purchase our common stock with the expectation of receiving cash dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><A NAME="s_11"></A>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our authorized capital stock consists of 150,000,000
shares of common stock, par value $0.01 per share, and 15,000,000 shares of preferred stock, par value $0.01 per share, and as
of December 31, 2017 there were 10,196,620 shares of common stock outstanding and 4,935 shares of preferred stock outstanding.
As of January 29, 2019, there were 48,368,593 shares of our common stock and 47 shares of Series B preferred stock outstanding.
In addition, as of January 29, 2019, options to purchase 3,399,076 shares of our common stock were outstanding at a weighted average
exercise price of $1.06 per share, 2,665,289 shares of our common stock were reserved for future grants under our stock option
plans and warrants to purchase 13,763,608 shares of our common stock were outstanding at a weighted average exercise price of $1.25
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following description of our capital stock
and provisions of our amended and restated certificate of incorporation, amended and restated by-laws and certificate of designation
are summaries of material terms and provisions and are qualified by reference to our amended and restated certificate of incorporation,
amended and restated by-laws and certificates of designation, copies of which have been previously filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may issue shares of our common stock from
time to time. Holders of our common stock are entitled to one vote per share on all matters to be voted upon by the stockholders.
Holders of our common stock do not have cumulative voting rights in the election of directors. Subject to the preferences that
may be applicable to any then outstanding preferred stock, holders of common stock are entitled to receive ratably such dividends,
if any, as may be declared by our Board of Directors out of funds legally available therefor. Upon the liquidation, dissolution,
or winding up of our company, holders of common stock are entitled to share ratably in all of our assets which are legally available
for distribution after payment of all debts and other liabilities and liquidation preference of any outstanding preferred stock.
There are no sinking fund provisions applicable to our common stock. Holders of common stock have no preemptive, subscription,
redemption or conversion rights. The rights, preferences and privileges of holders of common stock are subject to, and may be adversely
affected by, the rights of the holders of shares of any series of preferred stock that we have designated and issued and may designate
and issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may issue shares of our preferred stock from
time to time, in one or more series. The 15,000,000 shares of preferred stock authorized are undesignated as to preferences, privileges
and restrictions, other than as set forth herein. Our Board of Directors will determine the rights, preferences and privileges
of the shares of each wholly unissued series, and any qualifications, limitations or restrictions thereon, including dividend rights,
conversion rights, terms of redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares constituting
any series or the designation of any series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The General Corporation Law of the State of
Delaware, the state of our incorporation, provides that the holders of preferred stock will have the right to vote separately as
a class (or, in some cases, as a series) on an amendment to our amended and restated certificate of incorporation if the amendment
would change the par value, the number of authorized shares of the class or the powers, preferences or special rights of the class
or series so as to adversely affect the class or series, as the case may be. This right is in addition to any voting rights that
may be provided for in the applicable certificate of designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our Board of Directors may authorize the issuance
of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders
of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, financings
and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control
and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock.
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Series B Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">On August 25, 2017, we
filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the &ldquo;Series
B Certificate of Designation&rdquo;) with the State of Delaware, which designates 6,900 shares of our preferred stock as Series
B Senior Convertible Preferred Stock (the &ldquo;Series B Preferred Stock&rdquo;). The Series B Preferred Stock has a stated value
of $1,000 per share and a par value of $0.01 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">If, prior to the second
anniversary of the original issue date of the Series B Preferred Stock, we sell or grant any option to purchase or sell or grant
any right to reprice, or otherwise dispose of or issue, any of our common stock or securities convertible into or exercisable for
shares of our common stock at an effective price per share that is lower than the then effective conversion price, then the conversion
price will be reduced to equal the higher of (A) such lower price or (B) $0.05, subject to an exception for the following types
of issuances (i) issuances to our employees, officers or directors pursuant to any stock or option plan adopted by a majority of
the non-employee members of our Board of Directors or committee thereof, (ii) issuances upon the exercise or exchange of any securities
issued in connection with the August 2017 Offering or convertible into shares of common stock issued and outstanding on the date
of the underwriting agreement entered into in connection with the August 2017 Offering, provided that such securities have not
been amended since the date of the underwriting agreement to increase the number of securities or decrease the exercise, exchange
or conversion price, or (iii) issuances pursuant to acquisitions or strategic transactions approved by a majority of the disinterested
members of our Board of Directors, provided that such securities are &ldquo;restricted securities&rdquo; under Rule 144 and carry
no registration rights that require or permit the filing of any registration statement in connection therewith during the 90-day
period following the original issuance date of the Series B Preferred Stock, and provided that any such issuance is to a person
or its equity holders that is an operating company or an owner of an asset in a business synergistic with the business of our company
and will provide our company with additional benefits in addition to the investment of funds, but will not include a transaction
in which we issue securities primarily for the purpose of raising capital or to an entity whose primary business is investing in
securities (the issuances referred to in (i) through (iii) above, the &ldquo;Exempt Issuances&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In the event of a liquidation,
the holders of Series B Preferred Shares are entitled to an amount equal to the par value of the Series B Preferred Stock and thereafter
to participate on an as-converted-to-common stock basis with holders of the common stock in any distribution of our assets to the
holders of the common stock. The Series B Certificate of Designation provides, among other things, that we will not pay any dividends
on shares of common stock (other than dividends in the form of common stock) unless and until such time as we pay dividends on
each Series B Preferred Share on an as-converted basis. Other than as set forth in the previous sentence, the Series B Certificate
of Designation provides that no other dividends will be paid on Series B Preferred Shares and that we will pay no dividends (other
than dividends in the form of common stock) on shares of common stock unless we simultaneously comply with the previous sentence.
The Series B Certificate of Designation does not provide for any restriction on the repurchase of Series B Preferred Shares by
us while there is any arrearage in the payment of dividends on the Series B Preferred Shares. There are no sinking fund provisions
applicable to the Series B Preferred Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In addition, in the event
we consummate a merger or consolidation with or into another person or other reorganization event in which our shares of common
stock are converted or exchanged for securities, cash or other property, or we sell, lease, license, assign, transfer, convey or
otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding shares
of common stock, then following such event, the holders of the Series B Preferred Shares will be entitled to receive upon conversion
of the Series B Preferred Shares the same kind and amount of securities, cash or property which the holders would have received
had they converted the Series B Preferred Shares immediately prior to such fundamental transaction. Any successor to us or surviving
entity is required to assume the obligations under the Series B Preferred Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Notwithstanding the foregoing,
in the event we are not the surviving entity of a fundamental transaction or in the event of a reverse merger or similar transaction
where we are the surviving entity, then, automatically and contemporaneous with the consummation of such transaction, the surviving
entity (or our company in the event of a reverse merger or similar transaction) will purchase the then outstanding shares of Series
B Preferred Stock by paying and issuing, in the event that such consideration given to the holders of our common stock is non-cash
consideration, as the case may be, to each holder an amount equal to the cash consideration plus the non-cash consideration in
the form issuable to the holders of our common stock (in the case of a reverse merger or similar transaction, shares of common
stock issuable to the holders of the acquired company) per share of our common stock in the fundamental transaction multiplied
by the number of shares of common stock underlying the shares of Series B Preferred Stock held by the holder on the date immediately
prior to the consummation of the fundamental transaction. Such amount will be paid in the same form and mix (whether securities,
cash or property, or any combination of the foregoing) as the consideration received by holders of our common stock in the fundamental
transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">With certain exceptions,
as described in the Series B Certificate of Designation, shares of Series B Preferred Stock, or Series B Preferred Shares, have
no voting rights. However, as long as any shares of Series B Preferred Shares remain outstanding, the Series B Certificate of Designation
provides that we may not, without the affirmative vote of holders of a majority of the then-outstanding Series B Preferred Shares,
(a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Shares or alter or amend the Series
B Certificate of Designation, (b) increase the number of authorized shares of Series B Preferred Shares or (c) amend our Certificate
of Incorporation or other charter documents in any manner that adversely affects any rights of holders of Series B Preferred Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Each Series B Preferred
Share is convertible at any time at the holder&rsquo;s option into a number of shares of common stock equal to $1,000 divided by
the Series B Conversion Price. The &ldquo;Series B Conversion Price&rdquo; was initially $2.50 and is subject to adjustment for
stock splits, stock dividends, distributions, subdivisions and combinations and, as discussed above, certain dilutive issuances
of our common stock or securities convertible into or exercisable for shares of our common stock. In November 2017, at the time
of our issuance of our Series C Preferred Stock, the conversion price of the Series B Preferred Stock was reduced from $2.50 per
share to $1.40 per share. In February 2018, we entered into an equity purchase agreement and, as a result, the conversion price
of the Series B Convertible Preferred Stock was automatically adjusted from the reduced $1.40 per share price to $1.04 per share.
On March 21, 2018, the Series B Conversion Price was reduced from $1.04 to $0.75 as a result of our letter agreement with certain
holders of shares of our Series B Preferred Stock and Series C Preferred Stock (the &ldquo;Letter Agreement&rdquo;). In April 2018,
as a result of a securities purchase agreement pursuant to which we agreed to issue up to approximately $3,296,703 in Senior Secured
Convertible Promissory Notes, the conversion price of the Series B Convertible Preferred Stock was automatically adjusted from
$0.75 per share to $0.30 per share On November 29, 2018, as a result of the Amendment Agreement, the conversion price of our Series
B Convertible Preferred Stock was automatically adjusted from $0.30 per share to $0.15 per share and is subject to further adjustment
as set forth in the Series B Certificate of Designation. Notwithstanding the foregoing, the Series B Certificate of Designation
further provides that we may not effect any conversion of Series B Preferred Shares, with certain exceptions, to the extent that,
after giving effect to an attempted conversion, the holder of Series B Preferred Shares (together with such holder&rsquo;s affiliates,
and any persons acting as a group together with such holder or any of such holder&rsquo;s affiliates) would beneficially own a
number of shares of our common stock in excess of 4.99% (or, at the election of the holder, 9.99%) of the shares of our common
stock then outstanding after giving effect to such exercise (the &ldquo;Preferred Stock Beneficial Ownership Limitation&rdquo;);
provided, however, that upon notice to us, the holder may increase or decrease the Preferred Stock Beneficial Ownership Limitation,
provided that in no event may the Preferred Stock Beneficial Ownership Limitation exceed 9.99% and any increase in the Preferred
Stock Beneficial Ownership Limitation will not be effective until 61 days following notice of such increase from the holder to
us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">As of January 29, 2019,
all but 47 shares of the Series B Preferred Stock had been converted to shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Series C Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">On November 6, 2017, we
filed a Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the &ldquo;Series
C Certificate of Designation&rdquo;) with the State of Delaware, which designates 2,748 shares of our preferred stock as Series
C Convertible Preferred Stock (the &ldquo;Series C Preferred Stock&rdquo;). The Series C Preferred Stock has a stated value of
$1,000 per share and a par value of $0.01 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">If prior to the second
anniversary of the original issue date of the Series C Preferred Stock, we sell or grant any option to purchase or sell or grant
any right to reprice, or otherwise dispose of or issue, any of our common stock or securities convertible into or exercisable for
shares of our common stock at an effective price per share that is lower than the then effective conversion price, then the conversion
price will be reduced to equal the higher of (A) such lower price or (B) $0.05, subject to an exception for the following types
of issuances (i) issuances to our employees, officers or directors pursuant to any stock or option plan adopted by a majority of
the non-employee members of our Board of Directors or committee thereof, (ii) issuances upon the exercise or exchange of any securities
issued in connection with our November 2017 Offering or convertible into shares of common stock issued and outstanding on the date
of the placement agency agreement entered into in connection with our November 2017 Offering, provided that such securities have
not been amended since the date of the placement agency agreement to increase the number of securities or decrease the exercise,
exchange or conversion price, or (iii) issuances pursuant to acquisitions or strategic transactions approved by a majority of the
disinterested members of our Board of Directors, provided that such securities are &ldquo;restricted securities&rdquo; under Rule
144 and carry no registration rights that require or permit the filing of any registration statement in connection therewith during
the 90-day period following the original issuance date of the Series C Preferred Stock, and provided that any such issuance is
to a person or its equityholders that is an operating company or an owner of an asset in a business synergistic with the business
of our company and will provide our company with additional benefits in addition to the investment of funds, but will not include
a transaction in which we issue securities primarily for the purpose of raising capital or to an entity whose primary business
is investing in securities (the issuances referred to in (i) through (iii) above, the &ldquo;Exempt Issuances&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In the event of a liquidation,
the holders of shares of Series C Preferred Stock, or Series C Preferred Shares, are entitled to an amount equal to the par value
of the Series C Preferred Stock and thereafter to participate on an as-converted-to-common stock basis with holders of the common
stock in any distribution of our assets to the holders of the common stock. The Series C Certificate of Designation provides, among
other things, that we will not pay any dividends on shares of common stock (other than dividends in the form of common stock) unless
and until such time as we pay dividends on each Series C Preferred Share on an as-converted basis. Other than as set forth in the
previous sentence, the Series C Certificate of Designation provides that no other dividends will be paid on Series C Preferred
Shares and that we will pay no dividends (other than dividends in the form of common stock) on shares of common stock unless we
simultaneously comply with the previous sentence. The Series C Certificate of Designation does not provide for any restriction
on the repurchase of Series C Preferred Shares by us while there is any arrearage in the payment of dividends on the Series C Preferred
Shares. There are no sinking fund provisions applicable to the Series C Preferred Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In addition, in the event
we consummate a merger or consolidation with or into another person or other reorganization event in which our shares of common
stock are converted or exchanged for securities, cash or other property, or we sell, lease, license, assign, transfer, convey or
otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding shares
of common stock, then following such event, the holders of the Series C Preferred Shares will be entitled to receive upon conversion
of the Series C Preferred Shares the same kind and amount of securities, cash or property which the holders would have received
had they converted the Series C Preferred immediately prior to such fundamental transaction. Any successor to us or surviving entity
is required to assume the obligations under the Series C Preferred Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Notwithstanding the foregoing,
in the event we are not the surviving entity of a fundamental transaction or in the event of a reverse merger or similar transaction
where we are the surviving entity, then, automatically and contemporaneous with the consummation of such transaction, the surviving
entity (or our company in the event of a reverse merger or similar transaction) will purchase the then outstanding shares of Series
C Preferred Stock by paying and issuing, in the event that such consideration given to the holders of our common stock is non-cash
consideration, as the case may be, to each holder an amount equal to the cash consideration plus the non-cash consideration in
the form issuable to the holders of our common stock (in the case of a reverse merger or similar transaction, shares of common
stock issuable to the holders of the acquired company) per share of our common stock in the fundamental transaction multiplied
by the number of shares of common stock underlying the shares of Series C Preferred Stock held by the holder on the date immediately
prior to the consummation of the fundamental transaction. Such amount will be paid in the same form and mix (whether securities,
cash or property, or any combination of the foregoing) as the consideration received by holders of our common stock in the fundamental
transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">With certain exceptions,
as described in the Series C Certificate of Designation, the Series C Preferred Shares have no voting rights. However, as long
as any shares of Series C Preferred Shares remain outstanding, the Series C Certificate of Designation provides that we may not,
without the affirmative vote of holders of a majority of the then-outstanding Series C Preferred Shares, (a) alter or change adversely
the powers, preferences or rights given to the Series C Preferred Shares or alter or amend the Series C Certificate of Designation,
(b) increase the number of authorized shares of Series C Preferred Shares or (c) amend our Certificate of Incorporation or other
charter documents in any manner that adversely affects any rights of holders of Series C Preferred Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Each Series C Preferred
Share is convertible at any time at the holder&rsquo;s option into a number of shares of common stock equal to $1,000 divided by
the Series C Conversion Price. The &ldquo;Series C Conversion Price&rdquo; was initially $1.40 and is subject to adjustment for
stock splits, stock dividends, distributions, subdivisions and combinations and, as discussed above, certain dilutive issuances
of our common stock or securities convertible into or exercisable for shares of our common stock. In February 2018, we entered
into an equity purchase agreement and, as a result, the Series C Conversion Price was automatically adjusted from $1.40 per share
to $1.04 per share. On March 21, 2018, the Series C Conversion Price was reduced to $0.75 as a result of the Letter Agreement.
All of the Series C Preferred Stock had been converted to shares of our common stock by March 31, 2018. Notwithstanding the foregoing,
the Series C Certificate of Designation further provides that we may not effect any conversion of Series C Preferred Shares, with
certain exceptions, to the extent that, after giving effect to an attempted conversion, the holder of Series C Preferred Shares
(together with such holder&rsquo;s affiliates, and any persons acting as a group together with such holder or any of such holder&rsquo;s
affiliates) would beneficially own a number of shares of our common stock in excess of 4.99% (or, at the election of the holder,
9.99%) of the shares of our common stock then outstanding after giving effect to such exercise (the &ldquo;Preferred Stock Beneficial
Ownership Limitation&rdquo;); provided, however, that upon notice to us, the holder may increase or decrease the Preferred Stock
Beneficial Ownership Limitation, provided that in no event may the Preferred Stock Beneficial Ownership Limitation exceed 9.99%
and any increase in the Preferred Stock Beneficial Ownership Limitation will not be effective until 61 days following notice of
such increase from the holder to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The Series C Certificate
of Designation provides that we will not be obligated to issue any shares of common stock, and a holder will not have the right
to convert any portion of the Series C Preferred Stock, if such issuance (taken together with any prior issuance of shares of common
stock upon conversion of the Series C Preferred Stock) would exceed 1,961,914 shares of common stock, which is the aggregate number
of shares of common stock which we may issue upon conversion of the Series C Preferred Stock without breaching our obligations
under the rules or regulations of the NASDAQ Capital Market, except that such limitation will not apply in the event that we (A)
obtain the approval of our stockholders as required by the applicable rules of the NASDAQ Capital Market for issuances of common
stock in excess of such number of shares of common stock or (B) obtain a written opinion from our outside counsel that such approval
is not required, which opinion will be reasonably satisfactory to the holder. Because we obtained the approval of our stockholders
on January 30, 2018, the foregoing limitation is no longer operative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The Series C Certificate
of Designation also prohibits us from issuing any shares of common stock or securities convertible or exercisable into common stock
at a price per share below the then effective conversion price of the Series C Preferred Stock, subject to certain exceptions,
or entering into any agreement or making any public announcement with respect to such a dilutive issuance, until we have filed
a proxy statement under Section 14(a) of the Exchange Act or information statement pursuant to Section 14(c) of the Exchange Act
with the SEC and obtained approval of the November 2017 Offering from our stockholders, including approval of issuances in excess
of the maximum number of shares issuable under the rules and regulations of the NASDAQ Capital Market. Because we filed a proxy
statement and obtained stockholder approval of the November 2017 Offering on January 30, 2018, the foregoing restriction is no
longer operative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Antitakeover Effects of Delaware Law and Provisions of our Amended
and Restated Certificate of Incorporation and Amended and Restated By-laws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Certain provisions of the Delaware General Corporation Law and of
our amended and restated certificate of incorporation and amended and restated by-laws could have the effect of delaying, deferring
or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage
certain types of coercive takeover practices and inadequate takeover bids and, as a consequence, they might also inhibit temporary
fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These
provisions are also designed in part to encourage anyone seeking to acquire control of us to first negotiate with our board of
directors. These provisions might also have the effect of preventing changes in our management. It is possible that these provisions
could make it more difficult to accomplish transactions that stockholders might otherwise deem to be in their best interests. However,
we believe that the advantages gained by protecting our ability to negotiate with any unsolicited and potentially unfriendly acquirer
outweigh the disadvantages of discouraging such proposals, including those priced above the then-current market value of our common
stock, because, among other reasons, the negotiation of such proposals could improve their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Delaware Takeover Statute</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We are subject to the provisions of Section&nbsp;203 of the Delaware
General Corporation Law. In general, Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a &ldquo;business
combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a three-year period following the time that this stockholder
becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section&nbsp;203,
a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following
conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">before
the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted
in the stockholder becoming an interested stockholder;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Section&nbsp;203 defines a business combination to include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD>any merger or consolidation involving the corporation and the interested stockholder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD>any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of
the corporation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In general, Section&nbsp;203 defines an interested stockholder as
any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person
affiliated with or controlling or controlled by the entity or person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Provisions of our Amended and Restated Certificate of Incorporation
and Amended and Restated By-laws</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our amended and restated certificate of incorporation and amended
and restated by-laws include a number of provisions that may have the effect of delaying, deferring or discouraging another party
from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals
to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include the items
described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Board composition and filling vacancies.</I> In accordance with
our amended and restated certificate of incorporation, our board is divided into three classes serving staggered three-year terms,
with one class being elected each year. Our amended and restated certificate of incorporation also provides that directors may
be removed only for cause and then only by the affirmative vote of the holders of 75% or more of the shares then entitled to vote
at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting
from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office
even if less than a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>No written consent of stockholders.</I> Our amended and restated
certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an
annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may
lengthen the amount of time required to take stockholder actions and would prevent the amendment of our by-laws or removal of directors
by our stockholder without holding a meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Meetings of stockholders.</I> Our amended and restated by-laws
provide that only a majority of the members of our board of directors then in office may call special meetings of stockholders
and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders.
Our amended and restated by-laws limit the business that may be conducted at an annual meeting of stockholders to those matters
properly brought before the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Advance notice requirements.</I> Our amended and restated by-laws
establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election
as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder
proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally,
to be timely, notice must be received at our principal executive offices not less than 90 days or more than 120 days prior to the
first anniversary date of the annual meeting for the preceding year. The notice must contain certain information specified in our
amended and restated by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Amendment to certificate of incorporation and by-laws.</I> As
required by the Delaware General Corporation Law, any amendment of our amended and restated certificate of incorporation must first
be approved by a majority of our board of directors, and if required by law or our amended and restated certificate of incorporation,
must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment, and a majority of the outstanding
shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action,
directors, limitation of liability and the amendment of our amended and restated certificate of incorporation must be approved
by not less than 75% of the outstanding shares entitled to vote on the amendment, and not less than 75% of the outstanding shares
of each class entitled to vote thereon as a class. Our amended and restated by-laws may be amended by the affirmative vote of a
majority vote of the directors then in office, subject to any limitations set forth in the amended and restated by-laws; and may
also be amended by the affirmative vote of at least 75% of the outstanding shares entitled to vote on the amendment, or, if the
board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding
shares entitled to vote on the amendment, in each case voting together as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Undesignated preferred stock.</I> Our amended and restated certificate
of incorporation provides for authorized shares of preferred stock. The existence of authorized but unissued shares of preferred
stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of
a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board
of directors were to determine that a takeover proposal is not in the best interests of us or our stockholders, our board of directors
could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions
that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard,
our amended and restated certificate of incorporation grants our board of director&rsquo;s broad power to establish the rights
and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease
the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely
affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing
a change in control of us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Choice of forum.</I> Our amended and restated by-laws provide
that the Court of Chancery of the State of Delaware is the sole and exclusive forum for any derivative action or proceeding brought
on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the
Delaware General Corporation Law, our certificate of incorporation or our by-laws, or any action asserting a claim against us that
is governed by the internal affairs doctrine. Although our amended and restated by-laws contain the choice of forum provision described
above, it is possible that a court could rule that such a provision is inapplicable for a particular claim or action or that such
provision is unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The transfer agent and registrar for our common stock is EQ Shareowner
Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our common stock is listed on The NASDAQ Capital Market under the
symbol &ldquo;PRPO.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>THE LINCOLN PARK TRANSACTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On September 7, 2018, we entered into the Purchase
Agreement and the Registration Rights Agreement with Lincoln Park. Pursuant to the terms of the Purchase Agreement, Lincoln Park
has agreed to purchase from us up to $10,000,000 of our common stock (subject to certain limitations) from time to time during
the term of the Purchase Agreement. Pursuant to the terms of the Registration Rights Agreement, we are required to file with the
SEC a registration statement that includes a prospectus to register for resale under the Securities Act the shares that have been
or may be issued to Lincoln Park under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the terms of the Purchase Agreement,
at the time we executed the Purchase Agreement and the Registration Rights Agreement, we issued 600,000 Commitment Shares to Lincoln
Park as consideration for its commitment to purchase shares of our common stock under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We do not have the right to commence any sales
to Lincoln Park under the Purchase Agreement until certain conditions set forth in the Purchase Agreement, all of which are outside
of Lincoln Park&rsquo;s control, have been satisfied, including the registration statement registering the shares being issued
and sold to Lincoln Park being declared effective by the SEC. Thereafter, we may, from time to time and at our sole discretion,
on any single business day on which the closing price of our common stock is not less than $0.10 per share (subject to adjustment
for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction as provided
in the Purchase Agreement), direct Lincoln Park to purchase shares of our common stock in regular purchases in amounts up to 450,000
shares which amounts may be increased to up to 550,000 shares depending on the market price of our common stock at the time of
sale and subject to a maximum commitment by Lincoln Park of $1,000,000 per singular regular purchase. The purchase price per share
sold in a regular purchase will be based on the market price of our common stock immediately preceding the time of sale as computed
under the Purchase Agreement. Lincoln Park may not assign or transfer its rights and obligations under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Under applicable rules of The NASDAQ Capital
Market, in no event may we issue or sell to Lincoln Park under the Purchase Agreement shares of our common stock in excess of the
Exchange Cap (which was 4,628,859 shares, or 19.99% of the shares of our common stock outstanding immediately prior to the execution
of the Purchase Agreement), unless (i) we obtain stockholder approval&nbsp;to issue shares of common stock in excess of the Exchange
Cap or (ii) the average price of all applicable sales of our common stock to Lincoln Park under the Purchase Agreement equals or
exceeds $0.4728 (which represented the closing consolidated bid price of our common stock on September 7, 2018, plus an incremental
amount to account for our issuance of the Commitment Shares to Lincoln Park), such that issuances and sales of our common stock
to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable NASDAQ rules. Stockholders&rsquo;
approval to issue shares of common stock in excess of the Exchange Cap was granted on December 20, 2018. As of the date of this
prospectus, we have already received approximately $1,615,396 from the sale of 6,400,000 shares of common stock to Lincoln Park
which were sold to Lincoln Park pursuant to the effective registration statement on Form S-1A (File No.: 333-227364) filed on September
13, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Purchase Agreement also prohibits us from
directing Lincoln Park to purchase any shares of common stock if those shares, when aggregated with all other shares of our common
stock then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park exceeding the Beneficial Ownership
Cap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Purchase of Shares Under the Purchase Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Under the Purchase Agreement, on any business
day selected by us on which the closing price of our common stock is not less than $0.10 per share (subject to adjustment for any
reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction as provided
in the Purchase Agreement), we may direct Lincoln Park to purchase up to 450,000 shares of our common stock in a regular purchase
on such business day, provided, however, that (i) the Regular Purchase may be increased to up to 500,000 shares, provided that
the closing sale price of our common stock is not below $0.50 on the purchase date (subject to adjustment for any reorganization,
recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction as provided in the Purchase
Agreement) and (ii) the Regular Purchase may be increased to up to 550,000 shares, provided that the closing sale price of our
common stock is not below $0.75 on the purchase date(subject to adjustment for any reorganization, recapitalization, non-cash dividend,
stock split, reverse stock split or other similar transaction as provided in the Purchase Agreement) (such share amount limitation,
the &ldquo;Regular Purchase Share Limit&rdquo;). In each case, Lincoln Park&rsquo;s maximum commitment in any single Regular Purchase
may not exceed $1,000,000. The Regular Purchase Share Limit is subject to proportionate adjustment in the event of a reorganization,
recapitalization, non-cash dividend, stock split or other similar transaction; provided, that if after giving effect to such full
proportionate adjustment, the adjusted Regular Purchase Share Limit would preclude us from requiring Lincoln Park to purchase common
stock at an aggregate purchase price equal to or greater than $100,000 in any single Regular Purchase, then the Regular Purchase
Share Limit will not be fully adjusted, but rather the Regular Purchase Share Limit for such Regular Purchase shall be adjusted
as specified in the Purchase Agreement, such that, after giving effect to such adjustment, the Regular Purchase Share Limit will
be equal to (or as close as can be derived from such adjustment without exceeding) $100,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The purchase price per share for each such Regular
Purchase will be equal to the lower of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the lowest sale price for our common stock on the purchase date of such shares; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the arithmetic average of the three lowest closing sale prices for our common stock during the 10 consecutive business days ending on the business day immediately preceding the purchase date of such shares.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition to Regular Purchases described above,
we may also direct Lincoln Park, on any business day on which we have properly submitted a Regular Purchase notice directing Lincoln
Park to purchase the maximum number of shares of our common stock that we are then permitted to include in a single Regular Purchase
notice and the closing sale price of our common stock on such business day is not below $0.25 per share (subject to adjustment
for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction as provided
in the Purchase Agreement), to purchase an additional amount of our common stock, which we refer to as an Accelerated Purchase,
not to exceed the lesser of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25% of the aggregate shares of our common stock traded during all or, if certain trading volume or market price thresholds specified in the Purchase Agreement are crossed on the applicable Accelerated Purchase date, which is defined as the next business day following the purchase date for the corresponding Regular Purchase, the portion of the normal trading hours on the applicable Accelerated Purchase date prior to such time that any one of such thresholds is crossed, which period of time on the applicable Accelerated Purchase date we refer to as the Accelerated Purchase Measurement Period; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 times the number of purchase shares purchased pursuant to the corresponding Regular Purchase.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The purchase price per share for each such Accelerated
Purchase will be equal to the lower of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96% of the volume weighted average price of our common stock during the applicable Accelerated Purchase Measurement Period on the applicable Accelerated Purchase date; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the closing sale price of our common stock on the applicable Accelerated Purchase date.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may also direct Lincoln Park, not later than
1:00 p.m., Eastern time, on a business day on which an Accelerated Purchase has been completed and all of the shares to be purchased
thereunder (and under the corresponding Regular Purchase) have been properly delivered to Lincoln Park in accordance with the Purchase
Agreement prior to such time on such business day, and provided that the closing price of our common stock on the business day
immediately preceding such business day is not less than $0.25 per share (subject to adjustment for any reorganization, recapitalization,
non-cash dividend, stock split, reverse stock split or other similar transaction as provided in the Purchase Agreement), to purchase
an additional amount of our common stock, which we refer to as an Additional Accelerated Purchase, of up to the lesser of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25%
of the aggregate shares of our common stock traded during a certain portion of the normal trading hours on such Accelerated Purchase
date as determined in accordance with the Purchase Agreement, which period of time we refer to as the Additional Accelerated Purchase
Measurement Period; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 times the number of purchase shares purchased pursuant to the Regular Purchase corresponding to the Accelerated Purchase that was completed on such Accelerated Purchase date on which an additional accelerated Purchase notice was properly received.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may, in our sole discretion, submit multiple
Additional Accelerated Purchase notices to Lincoln Park prior to 1:00 p.m., Eastern time, on a single Accelerated Purchase date,
provided that all prior Accelerated Purchases and Additional Accelerated Purchases (including those that have occurred earlier
on the same day) have been completed and all of the shares to be purchased thereunder (and under the corresponding Regular Purchase)
have been properly delivered to Lincoln Park in accordance with the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The purchase price per share for each such Additional
Accelerated Purchase will be equal to the lower of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96% of the volume weighted average price of our common stock during the applicable Additional Accelerated Purchase Measurement Period on the applicable Additional Accelerated Purchase date; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the closing sale price of our common stock on the applicable Additional Accelerated Purchase date.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In the case of the Regular Purchases, Accelerated
Purchases and Additional Accelerated Purchases, the purchase price per share will be equitably adjusted for any reorganization,
recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring during the business
days used to compute the purchase price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Other than as described above, there are no
trading volume requirements or restrictions under the Purchase Agreement, and we will control the timing and amount of any sales
of our common stock to Lincoln Park.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Events of Default</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0.25in">Events of default under the Purchase
Agreement include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness of the registration statement of which this prospectus forms a part lapses for any reason (including, without limitation, the issuance of a stop order), or any required prospectus supplement and accompanying prospectus are unavailable for the resale by Lincoln Park of our common stock offered hereby, and such lapse or unavailability continues for a period of 10 consecutive business days or for more than an aggregate of 30 business days in any 365-day period;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension by our principal market of our common stock from trading for a period of one business day;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the de-listing of our common stock from The NASDAQ Capital Market, our principal market, provided our common stock is not immediately thereafter trading on the New York Stock Exchange, the NASDAQ Global Market, the NASDAQ Global Select Market, the NYSE Market, the OTC Bulletin Board or OTC Markets (or nationally recognized successor thereto);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure of our transfer agent to issue to Lincoln Park shares of our common stock within two business days after the applicable date on which Lincoln Park is entitled to receive such shares;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any breach of the representations or warranties or covenants contained in the Purchase Agreement or Registration Rights Agreement that has or could have a material adverse effect on us and, in the case of a breach of a covenant that is reasonably curable, that is not cured within five business days;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if at any time the Exchange Cap is reached, to the extent applicable;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any voluntary or involuntary participation or threatened participation in insolvency or bankruptcy proceedings by or against us; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if at any time we are not eligible to transfer our common stock electronically.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Lincoln Park does not have the right to terminate
the Purchase Agreement upon any of the events of default set forth above. During an event of default, all of which are outside
of Lincoln Park&rsquo;s control, we may not direct Lincoln Park to purchase any shares of our common stock under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our Termination Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have the unconditional right, at any time,
for any reason and without any payment or liability to us, to give notice to Lincoln Park to terminate the Purchase Agreement.
In the event of bankruptcy proceedings by or against us, the Purchase Agreement will automatically terminate without action of
any party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>No Short-Selling or Hedging by Lincoln Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Lincoln Park has agreed that neither it nor
any of its affiliates shall engage in any direct or indirect short-selling or hedging of our common stock during any time prior
to the termination of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Prohibitions on Variable Rate Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">There are no restrictions on future financings,
rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement or Registration Rights
Agreement other than a prohibition on entering into a &ldquo;Variable Rate Transaction,&rdquo; as defined in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Effect of Performance of the Purchase Agreement on Our Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">All 15,000,000 shares registered in this offering
which have been or may be issued or sold by us to Lincoln Park under the Purchase Agreement are expected to be freely tradable.
It is anticipated that shares registered in this offering will be sold over a period of up to 24-months commencing on the date
that the registration statement including this prospectus becomes effective. The sale by Lincoln Park of a significant amount of
shares registered in this offering at any given time could cause the market price of our common stock to decline and to be highly
volatile. Sales of our common stock to Lincoln Park, if any, will depend upon market conditions and other factors to be determined
by us. We may ultimately decide to sell to Lincoln Park all, some or none of the additional shares of our common stock that may
be available for us to sell pursuant to the Purchase Agreement. If and when we do sell shares to Lincoln Park, after Lincoln Park
has acquired the shares, Lincoln Park may resell all, some or none of those shares at any time or from time to time in its discretion.
Therefore, sales to Lincoln Park by us under the Purchase Agreement may result in substantial dilution to the interests of other
holders of our common stock. In addition, if we sell a substantial number of shares to Lincoln Park under the Purchase Agreement,
or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangement with Lincoln Park
may make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might
otherwise wish to effect such sales. However, we have the right to control the timing and amount of any additional sales of our
shares to Lincoln Park and the Purchase Agreement may be terminated by us at any time at our discretion without any cost to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the terms of the Purchase Agreement,
we have the right, but not the obligation, to direct Lincoln Park to purchase up to $10,000,000 of our common stock. Depending
on the price per share at which we sell our common stock to Lincoln Park pursuant to the Purchase Agreement, we may need to sell
to Lincoln Park under the Purchase Agreement more shares of our common stock than are offered under this prospectus in order to
receive aggregate gross proceeds equal to the $10,000,000 total commitment available to us under the Purchase Agreement. If we
choose to do so, we must first register for resale under the Securities Act such additional shares of our common stock, which could
cause additional substantial dilution to our stockholders. The number of shares ultimately offered for resale by Lincoln Park under
this prospectus is dependent upon the number of shares we direct Lincoln Park to purchase under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Purchase Agreement prohibits us from issuing
or selling to Lincoln Park under the Purchase Agreement (i) shares of our common stock in excess of the Exchange Cap, unless we
obtain stockholder approval&nbsp;to issue shares in excess of the Exchange Cap, such consent was obtained on December 20, 2018,
or if the average price of all applicable sales of our common stock to Lincoln Park under the Purchase Agreement equal or exceed
$0.4728, such that the transactions contemplated by the Purchase Agreement are exempt from the Exchange Cap limitation under applicable
NASDAQ rules, and (ii) any shares of our common stock if those shares, when aggregated with all other shares of our common stock
then beneficially owned by Lincoln Park and its affiliates, would exceed the Beneficial Ownership Cap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following table sets forth the amount of
gross proceeds we would receive from our sale of shares being registered in this prospectus, to Lincoln Park under the Purchase
Agreement at varying purchase prices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Assumed Average<BR> Purchase Price Per<BR> Share</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Registered <BR>
Shares<BR> to be Issued if Full <BR>
Purchase<BR> (1)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of <BR>
Outstanding Shares<BR> After Giving Effect to <BR>
the Issuance<BR> to Lincoln Park (2)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Proceeds from the Sale of <BR>
Shares to<BR> Lincoln Park Under the <BR>
$10M<BR> Purchase Agreement</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 23%; text-align: right">0.15</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">15,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">23.7</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 22%; text-align: right">2,250,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.19</TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23.7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,850,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23.7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,384,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,384,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,192,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,384,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the Purchase Agreement provides that we may sell up to $10,000,000 of our common stock to Lincoln Park, we are only registering
at this time under the registration statement that includes this prospectus a total of 15,000,000 shares of our common stock that
may be sold to Lincoln Park as purchase shares under the Purchase Agreement, which may or may not cover all the shares we ultimately
sell to Lincoln Park under the Purchase Agreement, depending on the purchase price per share. As a result, we have included in
this column only those shares that we are registering in this offering. As of the date of this prospectus, we have already received
approximately $1,615,396 from the sale of 6,400,000 shares of common stock to Lincoln Park which were sold to Lincoln Park pursuant
to a registration statement on Form S-1A (File No.: 333-227364) filed on September 13, 2019.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
denominator is based on 48,368,593 shares of our common stock outstanding as of January 29, 2019, adjusted to include the number
of shares set forth in the adjacent column which we would have sold to Lincoln Park, assuming the purchase price in the adjacent
column. The numerator is based on the number of shares issuable under the Purchase Agreement at the corresponding assumed purchase
price set forth in the adjacent column.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
closing sale price of our shares on January 29, 2019.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B><A NAME="s_12"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The common stock offered by this prospectus
is being offered by the selling stockholder, Lincoln Park. The common stock may be sold or distributed from time to time by the
selling stockholder directly to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents
at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated prices, or at
fixed prices, which may be changed. The sale of the common stock offered by this prospectus could be effected in one or more of
the following methods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
brokers&rsquo; transactions;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transactions involving cross or block trades;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through brokers, dealers, or underwriters who may act solely as agents</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;at the market&rdquo; into an existing market for the common stock;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected through agents;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in privately negotiated transactions; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any combination of the foregoing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In order to comply with the securities laws
of certain states, if applicable, the shares may be sold only through registered or licensed brokers or dealers. In addition, in
certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption
from the state&rsquo;s registration or qualification requirement is available and complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Lincoln Park is an &ldquo;underwriter&rdquo;
within the meaning of Section 2(a)(11) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Lincoln Park has informed us that it intends
to use an unaffiliated broker-dealer to effectuate all sales, if any, of the common stock that it may purchase from us pursuant
to the Purchase Agreement. Such sales will be made at prices and at terms then prevailing or at prices related to the then current
market price. Each such unaffiliated broker-dealer will be an underwriter within the meaning of Section 2(a)(11) of the Securities
Act. Lincoln Park has informed us that each such broker-dealer will receive commissions from Lincoln Park that will not exceed
customary brokerage commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Brokers, dealers, underwriters or agents participating
in the distribution of the shares as agents may receive compensation in the form of commissions, discounts, or concessions from
the selling stockholder and/or purchasers of the common stock for whom the broker-dealers may act as agent. The compensation paid
to a particular broker-dealer may be less than or in excess of customary commissions. Neither we nor Lincoln Park can presently
estimate the amount of compensation that any agent will receive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We know of no existing arrangements between
Lincoln Park or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the shares
offered by this prospectus. At the time a particular offer of shares is made, a prospectus supplement, if required, will be distributed
that will set forth the names of any agents, underwriters or dealers and any compensation from the selling stockholder, and any
other required information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We will pay the expenses incident to the registration,
offering, and sale of the shares to Lincoln Park. We have agreed to indemnify Lincoln Park and certain other persons against certain
liabilities in connection with the offering of shares of common stock offered hereby, including liabilities arising under the Securities
Act or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Lincoln Park
has agreed to indemnify us against liabilities under the Securities Act that may arise from certain written information furnished
to us by Lincoln Park specifically for use in this prospectus or, if such indemnity is unavailable, to contribute amounts required
to be paid in respect of such liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Lincoln Park has represented to us that at no
time prior to the Purchase Agreement has Lincoln Park or its agents, representatives or affiliates engaged in or effected, in any
manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200 of Regulation SHO of the Exchange
Act) of our common stock or any hedging transaction, which establishes a net short position with respect to our common stock. Lincoln
Park agreed that during the term of the Purchase Agreement, it, its agents, representatives or affiliates will not enter into or
effect, directly or indirectly, any of the foregoing transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.75in">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have advised Lincoln Park that it is required
to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M precludes the selling stockholder,
any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing,
or attempting to induce any person to bid for or purchase any security which is the subject of the distribution until the entire
distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security
in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered
by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This offering will terminate on the earlier
of (i) termination of the Purchase Agreement or (ii) the date that all shares offered by this prospectus have been sold by Lincoln
Park.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our common stock is quoted on The NASDAQ Capital
Market under the symbol &ldquo;PRPO&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="s_13"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">The validity of the
common stock offered hereby will be passed upon for us by Sichenzia Ross Ference LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="s_14"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">The consolidated financial
statements of Precipio, Inc. (formerly Transgenomic, Inc.) as of and for the years ended December 31, 2017 and 2016 appearing in
our Annual Report on Form 10-K filed for the year ended December 31, 2017, have been audited by Marcum LLP, independent registered
public accounting firm, to the extent and for the periods as set forth in their report thereon, and incorporated herein by reference
in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="s_15"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">We have filed with
the SEC a registration statement on Form S-1 under the Securities Act that registers the shares of our common stock to be sold
in this offering. This prospectus does not contain all of the information set forth in the registration statement and the exhibits
and schedules filed as part of the registration statement. For further information with respect to us and our common stock, we
refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Statements
contained in this prospectus concerning the contents of any contract or any other document, are not necessarily complete. If a
contract or document has been filed as an exhibit to the registration statement, we refer you to the copy of the contract or document
that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all
respects by the filed exhibit. The reports and other information we file with the SEC can be read and copied at the SEC&rsquo;s
Public Reference Room at 100 F Street, NE, Washington D.C. 20549. Copies of these materials can be obtained at prescribed rates
from the Public Reference Section of the SEC at the principal offices of the SEC, 100 F Street, NE, Washington D.C. 20549. You
may obtain information regarding the operation of the public reference room by calling 1(800) SEC-0330. The SEC also maintains
a web site (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers
like us that file electronically with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">We are required to
file annual, quarterly and current reports and other information with the SEC under the Securities Exchange Act of 1934, as amended.
These periodic reports, proxy statements and other information will be available for inspection and copying at the SEC&rsquo;s
public reference room and the web site of the SEC referred to above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="s_16"></A>MARKET AND INDUSTRY DATA AND FORECASTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">Market data and certain
industry data and forecasts included in this prospectus were obtained from internal company surveys, market research, publicly
available information, reports of governmental agencies and industry publications and surveys. We have relied upon industry publications
as our primary sources for third-party industry data and forecasts. Industry surveys, publications and forecasts generally state
that the information contained therein has been obtained from sources believed to be reliable, but that the accuracy and completeness
of such information is not guaranteed. We have not independently verified any of the data from third-party sources, nor have we
ascertained the underlying economic assumptions relied upon therein. Similarly, internal surveys, industry forecasts and market
research, which we believe to be reliable based upon our management&rsquo;s knowledge of the industry, have not been independently
verified. Forecasts are particularly likely to be inaccurate, especially over long periods of time. In addition, we do not know
what assumptions regarding general economic growth were used in preparing the forecasts we cite. Statements as to our market position
are based on recently available data. While we are not aware of any misstatements regarding our industry data presented herein,
our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under
&ldquo;Risk Factors&rdquo; in this prospectus. While we believe our internal business research is reliable and market definitions
are appropriate, neither such research nor definitions have been verified by any independent source. This prospectus may only be
used for the purpose for which it has been published.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="s_17"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">This prospectus omits
some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information
and exhibits included in the registration statement of which this prospectus is a part for further information about us and the
securities we are offering. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement
or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You
should review the complete document to evaluate these statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">The SEC allows us to
&ldquo;incorporate by reference&rdquo; information we file with it, which means that we can disclose important information to you
by referring you to other documents. The information incorporated by reference is considered to be a part of this prospectus. Information
contained in this prospectus supersedes information incorporated by reference that we have filed with the SEC prior to the date
of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">We incorporate by reference
the following documents listed below (excluding any document or portion thereof to the extent such disclosure is furnished and
not filed):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Annual Report on Form&nbsp;10-K&nbsp;for the fiscal year ended December&nbsp;31, 2017, filed with the SEC on April&nbsp;13, 2018;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Quarterly Report on Form 10-Q for the quarter ended March 31 2018, filed with the SEC on May 21, 2018, our Quarterly Report on Form 10-Q for the quarter ended June 30 2018, filed with the SEC on August 16, 2018 and our Quarterly Report on Form 10-Q for the quarter ended September 30 2018, filed with the SEC on November 19, 2018;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Current Reports on Form&nbsp;8-K&nbsp;filed with the SEC January 31, 2018, February 9, 2018, February 13, 2018, February 26, 2018, March 14, 2018, March 21, 2018, March 30, 2018, April 23, 2018, April 26, 2018, May 14, 2018, June 4, 2018, June 15, 2018, July 6, 2018, ,July 18, 2018 August 9, 2018, August 22, 2018, September 13, 2018, September 20, 2018, September 25, 2018, September 27, 2018, October 16, 2018,November 16, 2018, December 3, 2018, December 20, January 7, 2019, January 22, 2019 and January 30, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 120.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The portions of our definitive proxy statement on Schedule 14A relating to our 2018 Annual Meeting of Stockholders, as filed with the SEC on May 29, 2018 that are deemed &ldquo;filed&rdquo; with the SEC under the Exchange Act and the portions of our definitive proxy statement on Schedule 14A relating to our Special Meeting of Stockholders, as filed with the SEC on November 11, 2018 that are deemed &ldquo;filed&rdquo; with the SEC under the Exchange Act.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">In addition, we hereby
incorporate by reference into this prospectus all documents that we file with the SEC under Sections 13(a), 13(c), 14, or 15(d)
of the Exchange Act after the effective date of this Registration Statement and before we terminate the offering under this prospectus.
These documents include periodic reports, such as annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports
on Form 8-K (other than current reports or portions thereof furnished under Items 2.02 or 7.01 of Form 8-K, unless specifically
incorporated herein), as well as proxy statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">We will provide without
charge to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, upon written or oral request,
a copy of any or all of the foregoing documents which we incorporate by reference in this prospectus (not including exhibits to
such documents unless such exhibits are specifically incorporated by reference to such documents). Requests should be directed
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Precipio, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">4 Science Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">New Haven, CT 06511</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(203)&nbsp;787-7888</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">A copy of any or all
of the foregoing documents which we incorporate by reference in this prospectus may be accessed on our corporate web site at&nbsp;<U>http://www.precipiodx.com</U>&nbsp;(Click
the &ldquo;Investors&rdquo; link and then the &ldquo;SEC Filings&rdquo; link).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp; <B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Up to 15,000,000</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>February 13, 2019 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 43; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img01.jpg
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M P,# __  !$( %<!R ,!$0 "$0$#$0'_Q #@    !04! 0
M @,)"@$$!0<(!@L!  $$ P$!               ! @,$!08'" D0  $# @4"
M P,( P@)#1$!  $" P01!0 A$@8',0A!$PE182)Q@9&A,A05"D)2(['18C,6
M%Q@9\,&"HM)3LR0HX?&2LI.CTY34595W.'+B0W.#-+0E176U1E9V-V=8*1$
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MI.:6BIJ&$^(9UHHC#/$K7![=0R2(8<A# A# A# A# A# A# A# A# A# A#
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MI+TE8+^@/ZY9Z=[.V_\ CR_[<3/%B3<MBK7P8A_8127B7(?T!O7,IGWM;?\
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MLZH0A24FO@"1C6&;OLD=_22"$Q5RT"E*]"NL#J*X3Z8/K&4'^G2CI_SS<_\
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M\DMXVUSG;<PM&-*4'U+AMUJXVB<W'E,S;-?&5)0 &519$%QE04EQ9<T+0X"
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MO0C&0>'AE <:(ITI%2"RK]GJ)"5.::_:T^%3X*4K&/CC>^<8]U&285]9'O\
MMZ\,V_:':CV].KG]QO.+C=JC)M;BG)6V[/.<6PY*6I@*7'6\A2A4T^$8W+;K
M1E!,X5;7 'U^15IL!UU7M_3*])_COM?VS;^4^6+5$Y([B]SL?C>XMT[G#=T<
MLDR[C[X["B*F^:K4RXX3JI5/3$E_NWA@6\9T@YD9]=$ENT4).=4]DPPTW5"$
M (2E 3H 2UD"-+:442$I&0H!3&N2RF7W,7JP6JX\M"OM &G3PI]%,4]%PTDD
MYI6D-5%-(RH!E7Q. _$=)3O%:,RB!EM*RX$C601JJ?'(]?:,(6S.8X$FE$A>
MUV6:;_\ 5,0G^@/W))H,N.;P /8 R<A]&-@Y2@ O>]QJ?-112FH)ZESEZ#J4
MCTX>(  *&3?A0#P^_N>SY<9+FAS6WC0, &_65#![R>.#2-2=*0DA.@$ 5">M
M![,\:H]SG>ZK:JN.@YJ!61X5S]GA3PQ$(IP:U11$##8-?*(]Y42/G%<\/TS\
M#BFZ1UHQ9;H:)2#X'2/WL(YUQ&TO<30)-(."T_SGPWL7G;C#=G&>_++!O5BW
M!9;A;UQIT1J4&7I$5QMF5&\U*E-R8SA"D*!%",6]CW$B]$F8#A7LJAS T4R4
M=?T)-QW[A[N![ONRF9<)$[:W&6])%TVFRZ\XZB!#7/FH=9:2I2DLI("0H#(T
MQO7-'@RPME'OAOK502GQ .!*[._, H3_ %=?(N5*7RPH %0 DO@D4Z4KBE\M
M/ZK<?<*DO,PNTO39)5V)]KJR?C7Q782I1\5>2\D$^!("!]&-5WX_[NFZ-;OX
M5)9>X>TK4/JD]^$#L;X$FWNWNMW+E+?#[6VN-=OJ(>>D7B4DQFYB8R:O:$R%
M@Z@"*XR6U6?B2!Q]T$U]BF3=OIA^EVYN><SWI=[D:1R'S7R&]_*"R;6W&ER9
M;]K,+69#,F0U,)2'D)6-(I2GAC)[EN8LAX45 0,^CR( '%23XEO@PX<>%#BQ
MHL*.AM,>-&:0S':0A(2@-M-I2@)2D #+IC3W&X>\R G$U\Z/%C5PF(TE2UI^
M%3M"X4Y:J=![@/=A--QTE+XK%8W"T6^[PYULN<1J;!FLN,2HTI")$>0TXDI<
M0XRZE2%)6DD$4P^VDEL)/'<[C4=29H%=?2HRWJ=^F->>)+PGOA[%&GN/N4./
MWG]S;NVI82N):[[!@J3)F2&(40AM+LIMLA22D@^S&[[=OS=VC^'EH9,@>E5I
M7AN#4ZMZ9'?/8^^/MYL6^]3<'?\ MU+&W.1MN-J"G[=N"$"V_(#:J.^7(4FJ
MS2FHG&$W*R^%G=&>FOU_6IX3KC#BG(4MH0%432I/B?=[\89TLE:$IT;G3@ME
M.IJ3#2:D@@=:FM#\F7NQ1NH776!Q%$&&WM^_&P-=Y48,-*;4DIRJ59*4*G.I
M)216N)8I1!&V)HQ: $XEP8'L-#2JL'K=&D)4AUA#K2@I*FEA2FE)6**"VLVU
MZA[0<12B"<_]2P.'6JI8;[NW7XC.@KD?FSLJ[>.:V9*-S\>VE%T<;<0;I9(3
M4">WK&:W78_E%Q0)K4@_+C7-[Y*V_>K0@L'@G(<!Z05I'-'RVVG?+=X=$WPW
M=O\ >"9NYJ]';>ME-PN_"V[$W2,V?,AV*[I4S+::;&M#33["DI+J5#X%?; I
MGCA]Q\J9;"[,VT,$4@XMH:?O.7G>\^2TNUW9GV>,1O!S;PQ_:<5L;M&[K.;N
MV2[P.%.Z?;FY+/MEM],"P;OFPI$N!;S(4$QF)-S*"DQ5Y4*U**1XXW?EN3F+
M:7-VW<)G2 &HKI% <>"ZER4>8MEMV[5N$KI '$BND4!->'M3^^W[W%W!:8-W
MMTJ'/B36TOLR(,AN3'?8<2E3;K;C9( 6DUH<QCL]JR.2 .>.\0NYVC620!SQ
MWB%GDDDU(T@BJ1[J#/YSAP%)#&/<IDCW9 P>Y5%6A"E455(IF00E*M1*=*CU
MZ^RF*QBCCN1I% G2QLTY"JAZ^K-WR<A[VY.W+VZW38-@L]FX[W*1!OCK7GW>
M6D"K4R,IS40VXWU!^&OACTM\M.5;&XL);VX;XDNIM*U%,*X4*YIS:&2OCUCW
M00/.F3KC>;C>'):KA(6N,^\IUUMQ3C84ZAJD<J:2I+9!4@4 %!3';W[+;R[6
M]LC 6AF7T*T>Q:([D:5-X](;DF1R)V4\?F=)$BY;6\_;\HE04M/W9PEG41TH
MV0!\F/&G.NWPV6[N$3 UKB5VCEYQ?$X.QH G349H!/L'[@QI^EO0LZ[#)(+<
M4%$4*LLA2M#[<J'%6ZN/A(Q(UM2311,+G/H<J(J5N=05 ]/XNOU UQ6;N$DF
M3/IYE, .*,7'/$FG_BBGZRJF)'W$^FK!C].I-=H [V21=< 25'0#D 724(J2
M  5)U&IKEEUPP7<V4K21].I,I;G@/2L3=[E&MUNDW*5(C1(D))?G29<@1H<:
M*R0X_(5(=#: AIM))).=*8FM98+N=MLZ/WC3CGP0/")H!BHFG/&_8OJ1>KMP
MAL+BA"=Q\8]LTM5WW-NB,I4BW2I3,T./N1I*26BTTXBA 5UQO]M%)MUM1G<
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M(QIL-QXC:QLP4WBQY(ZE'P2 ?::I'SD%1'T88^XG8:N%6]'T"<Q[2:(NI?\
M ^92EGYDZ17$?Q[N#/3^A2'31 ZU @*S(-*MJ KX9ZL-DNI;AA@#*%XI5(-(
M-5SKW*]Q&QNVOB#>'*>_]P6VR6_;MFF266+BXW#DW"XM,+7'BP6W5ZY)?<
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M.>.?09'M63=P5WB=-0P(0P(1%BH^G]S$;_?9]Y.;@4WKZIH'] ON3_ZM[O\
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M/.D8KQ'#?:[R/LW:EFYEWKQ]?;;MW<$=$K:4Z?!>,:7"=*DLST3 WY3064U
M5X8V.'F:"28QUP7-.9[&^9&^1E0VG!;M6E*G6_/<;4LI+Y(4-5*U#25THCWD
M>.,XXV%['5P:0>E<#O+K>;:Y(87 5X$^Q>PLO)6_-LMJ=VWO#<]GCH2YKCQ;
M].$9#904%M+ =\G2H'/+/&'BV7;YMRJUK:4' +:-CWG=#;-$[G:@XYDKF>[S
M'IMVG72:5/ORY4A^3,6I1DRW75%2W'UG,JJ<=BV7EK:H80^1K<1T!=/VC<[E
MP!>36G2L:@!3:JJ0&DI);*DI"]1-0$E-%E?U8DO[>PM;UHMP S0*Y9U*N;J^
M[N)6NAK0-]J7996HQ4)9?7(D$(892TX[(DN*-$,,1V@I:G5J( J*8FO-_LK.
MV[Q P^G%0;?MUS+)62N:?+].KTH-Z\QWVP<L\]VQW;'&L%<>YVS;,MHLW#<*
MFUA]@3FG %)BE2!6@K0XX'S]\Q;:%K;>T?\ BN:< :?6NB;=LE*%PP*EM[9V
MY;]KV:#9;+!C6FW6^,Q$M\"&RAJ+#B1VTM--,M@ 9H3\1.9QY<W.YOK^\\8E
MQ:3GTK=K>W;!'1H"]6T5$JJ   *#W^)Q>:UK8Q3.B5KM3B.A**3J%*D=,QA4
M]6[S"2%$%02H@K2CX=5 >I&?7#FO$9U%"I'10J615734>I%<DD]54'B<1OE#
MAADE5R.N(F :ZH1L3I$,"$#GE@0DU(H"16H!I\OAX8:XD-)&=$)!"#\.NI4E
M14@DZBFIZ)J,@!E\F(&23G@:'-"N\6,QBA#"H0P(5DA"D?HY42 <M5$FHJKJ
MK/VXHM-P30UHC#@KK17J3]7[V)FQ:A5^:%:*87JJ*A-3\*31*JGJH?I8G$8I
M[[E'X8KD$JAI82D*<)-,Z( %?< *"F&ECJX/=3R(\,=2/H/MK[\-,SV=VE:<
M4TP XU0T8/B'_91\..E$\K.OA@^)?T*,V@+JUP1'&P2D?%\*@L45I!(%!J ^
MT!B5DV./%3QL,8H,D&]: E- H)KF: YDGH,LJX<XAQJ,E(357:3J%>F>&I$F
MMO6?M* *=-$^&=:@TK7%:>W,S@X$B@2A(*;*"2WJ!5IJ:TKIR^(=%5'T8?';
MN:/?*< WC15TE9)5J2,J)2J@'6IR'CB5\G@\=55&]HPI1 H*2"G4?^Z57]W$
M+KIYR&"C+ 4-"U$&I"AT(I05ZU!R-1AK)97$@X!.8T U1%L$5"!Y:%=4(TIH
MHFI6E0HI)-*>S$FJ3I*DP1T)65#431(HG,?",JU_6)IU.(WASA0H5'HX4D_$
MOK5(2:!/R >&+4<[6"AIDC$*K05KJOXCJ)2J@24ITT"/A^T![\5_>E#@A7>)
MTB&!"&!"HK-*A[C^YA'5+2!G1"LM).JHJ5 )KD* =![_ )\,@,C!1V02UXHH
M9 "AIJ5@)<4554L>PFOP_-A+@R24#?=14J]H*=3]7[V'"DK48U2993IH"H56
M%DIHG40>A %*'!A"*A"24"H_Q?2M#4@U]H-<CB'XJ3@$^C.I)>6X#4%68^*M
M%%76IJ<P37"?%2="7N=2N$- !--0 33237ZSGA1+*XUZ4PT2A:!TU)HGPRS^
M7+PQ.TN([V::57RQJU?)D.F5/WL.RR0E,"$,"$B:DJH:9D=*BE?$>)PM<, H
MR230C"JT9SG:^$KMLRZ0^>I7'T7CR0TS^(/<DW*Q6S;+>A8.E4N_2H<&.XM5
M/B\P&N)89[V,GP&//30$]E<$U\<+O>< 5YJ]V3MM<XCM-IW!,XJ_F8%J:9LD
MBXWG;3&R?P@H4(ZK9=GIJ+8J.E!^%QMXI-*UQ8M]PWAEQJA@E,O4UQ]%%2W&
MRVR>S\.XFC9'TD@>LA,P\Y]C/IK;XDS[AL#N^X+XXN[X<<8@CFSC21;&G5#X
MD-QW-RH4TWYG49TQO=AS!S((]+K"<D<=$F/DT+C^X<J<I/E+SNMJUW1KB_\
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E?K84:*<%%I/2AI'ZV%[G4C0?M(U#[?J&%PX*08"BK@0A@0O_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
